

## Annexes

1. Fucà G, **de Braud F**, Di Nicola M. Immunotherapy-based combinations: an update. *Curr Opin Oncol*. 2018 Jul 9. doi: 10.1097/CCO.0000000000000466. [Epub ahead of print] PMID:29994900
2. Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, Cona MS, Maggi C, Ferrari B, Manoukian S, Mariani G, Bianchi G, Capri G, Rivoltini L, **de Braud F**. The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. *Sci Rep*. 2018 Jun 7;8(1):8703. doi: 10.1038/s41598-018-27075-z. PMID:29880896
3. Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, **de Braud F**, Di Nicolantonio F, Cremolini C, Pietrantonio F. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. *Ann Oncol*. 2018 May 31. doi: 10.1093/annonc/mdy197. [Epub ahead of print] PMID:29860358
4. Gennaro M, Di Cosimo S, Ardoino I, Veneroni S, Mariani L, Agresti R, Daidone MG, **de Braud F**, Apolone G, Biganzoli E, Demicheli R. Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. *Breast*. 2018 Aug;40:131-135. doi: 10.1016/j.breast.2018.05.004. Epub 2018 May 14.
5. Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregini E, Maccauro M, Coppa J, Milione M, Mazzaferro V, **de Braud F**. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. *Tumori*. 2018 Apr 1;300891618765362. doi: 10.1177/0300891618765362. [Epub ahead of print] PMID: 29714658
6. Toffalorio F, Santarpia M, Radice D, Jaramillo CA, Spitaleri G, Manzotti M, Catania C, Jordheim LP, Pelosi G, Peters GJ, Tibaldi C, Funel N, Spaggiari L, **de Braud F**, De Pas T, Giovannetti E. 5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer. *Oncotarget*. 2018 Feb 16;9(23):16437-16450. doi: 10.18632/oncotarget.24505. eCollection 2018 Mar 27. PMID:29662657
7. Nichetti F, Marra A, Corti F, Guidi A, Raimondi A, Prinzi N, **de Braud F**, Pusceddu S. The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. *Target Oncol*. 2018 Jun;13(3):333-351. doi: 10.1007/s11523-018-0567-0. PMID: 29656320
8. Pusceddu S, Vernieri C, Di Maio M, Marconcini R, Spada F, Massironi S, Ibrahim T, Brizzi MP, Campana D, Faggiano A, Giuffrida D, Rinzivillo M, Cingarlini S, Aroldi F, Antonuzzo L, Berardi R, Catena L, De Divitiis C, Ermacora P, Perfetti V, Fontana A, Razzore P, Carnaghi C, Maria VD, Cauchi C, Duro M, Sergio SR, Fazio N, Cavalcoli F, Bongiovanni A, La Salvia A, Brighi N, Colao A, Puliafito I, Panzuto F, Ortolani S, Zaniboni A, Di Costanzo F, Torniai M, Bajetta E, Tafuto S, Garattini SK, Femia D, Prinzi N, Concas L, Lo Russo G, Milione M, Giacomelli L, Buzzoni R, Delle Fave G, Mazzaferro V, **de Braud F**. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With

Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. *Gastroenterology*. 2018 Apr 13. pii: S0016-5085(18)30443-8. doi: 10.1053/j.gastro.2018.04.010. [Epub ahead of print] PMID:29655834

9. Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, **De Braud F**, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. *Endocr Relat Cancer*. 2018 Jun;25(6):607-618. doi: 10.1530/ERC-17-0489. Epub 2018 Mar 20.
10. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, **de Braud F**, Cremolini C. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. *Ann Oncol*. 2018 Jun 1;29(6):1394-1401. doi: 10.1093/annonc/mdy090. PMID: 29538669
11. Cremolini C, Milione M, Marmorino F, Morano F, Zucchelli G, Mennitto A, Prisciandaro M, Lonardi S, Pellegrinelli A, Rossini D, Bergamo F, Aprile G, Urbani L, Morelli L, Schirripa M, Cardellino GG, Fassan M, Fontanini G, **de Braud F**, Mazzaferro V, Falcone A, Pietrantonio F. Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. *Br J Cancer*. 2018 Apr;118(7):955-965. doi: 10.1038/s41416-018-0015-z. Epub 2018 Mar 13.
12. De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. *Lancet Oncol*. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub 2018 Feb 23. Erratum in: *Lancet Oncol*. 2018 Apr;19(4):e184.
13. Vernieri C, Nichetti F, Raimondi A, Pusceddu S, Platania M, Berrino F, **de Braud F**. Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. *Crit Rev Oncol Hematol*. 2018 Mar;123:57-73. doi: 10.1016/j.critrevonc.2018.01.002. Epub 2018 Feb 2. Review. PMID:29482780
14. Ratta R, Verzoni E, Di Maio M, Grassi P, Colecchia M, Fucà G, **de Braud F**, Procopio G. Exposure to Multiple Lines of Treatment and Survival of Patients With Metastatic Renal Cell Carcinoma: A Real-world Analysis. *Clin Genitourin Cancer*. 2018 Feb 5. pii: S1558-7673(18)30075-2. doi: 10.1016/j.clgc.2018.01.016. PMID: 29478961
15. Procopio G, Ratta R, **de Braud F**, Verzoni E. Combination therapies for patients with metastatic renal cell carcinoma. *Lancet Oncol*. 2018 Mar;19(3):281-283. doi: 10.1016/S1470-2045(18)30092-5. Epub 2018 Feb 10. PMID:29439858
16. Galli G, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, **de Braud F**, Garassino MC, Lo Russo G. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A

case series and literature review. *Lung Cancer*. 2018 Jan;115:135-142. doi: 10.1016/j.lungcan.2017.12.002. Epub 2017 Dec 5. Review.PMID:29290256

17. Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, **de Braud F**, Di Cosimo S. Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. *Breast Care (Basel)*. 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12.
18. Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fucà G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, **de Braud F**, Cremolini C. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. *J Natl Cancer Inst*. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx089.
19. Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, **Braud F**, Del Vecchio M. Innovative Therapy, Monoclonal Antibodies and Beyond. *Cytokine Growth Factor Rev*. 2017 Dec;38:1-9. doi: 10.1016/j.cytogfr.2017.10.002.
20. Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fucà G, Volpi C, Milione M, Di Maio M, Fontanini G, **De Braud F**, Falcone A, Pietrantonio F. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. *Ann Oncol*. 2017 Dec 1;28(12):3009-3014. doi: 10.1093/annonc/mdx546.
21. Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, **de Braud F**, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraud E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. *Nature*. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673.
22. Pietrantonio F, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, **de Braud F**, Giordano S, Cremolini C, Di Bartolomeo M. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clin Cancer Res*. 2017 Dec 5. doi: 10.1158/1078-0432.CCR-17-2781.
23. Cavalieri S, Stathis A, Fabbri A, Sonzogni A, Perrone F, Tamborini E, Pelosi G, **de Braud F**, Platania M. Uncommon somatic mutations in metastatic NUT midline carcinoma. *Tumori*. 2017 Nov 15;103(Suppl. 1):e5-e8. doi: 10.5301/tj.5000685.
24. Nichetti F, Morano F, Fabbri A, **de Braud F**, Di Bartolomeo M. Bilateral parotid gland metastases from gastric signet-ring cell carcinoma. *Tumori*. 2017 Nov 22:0. doi: 10.5301/tj.5000690.
25. Kim SB, Dent R, Im SA, Espiè M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-

blind, placebo-controlled, phase 2 trial. *Lancet Oncol.* 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3.

26. Grassi P, Verzoni E, Ratta R, Porcu L, Prisciandaro M, Mennitto A, Calareso G, **de Braud F**, Procopio G. Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? *Drugs R D.* 2017 Sep;17(3):461-467. doi: 10.1007/s40268-017-0203-y.
27. Milione M, Maisonneuve P, Pellegrinelli A, Pusceddu S, Centonze G, Dominoni F, Brambilla C, Rubino M, Faggiano A, Buzzoni R, Concas L, Giacomelli L, Coppa J, Mazzaferro V, **de Braud F**. Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors. *Endocrine* 2017 Sep;57(3):512-517. doi: 10.1007/s12020-016-1180-6.
28. Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, **de Braud F**, Garassino MC, Lo Russo G. Cognitive impairment and chemotherapy: a brief overview. *Crit Rev Oncol Hematol.* 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Review.
29. Cavalieri S, Morelli D, Martinetti A, Galli G, Nichetti F, **de Braud F**, Platania M. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. *Int J Biol Markers.* 2017 Sep 25:0. doi: 10.5301/ijbm.5000305. PMID:28967066
30. Pietrantonio F, Di Bartolomeo M, Cotsoglou C, Mennitto A, Berenato R, Morano F, Coppa J, Perrone F, Iacovelli R, Milione M, Alessi A, Vaiani M, Bossi I, Ricchini F, Scotti M, Caporale M, Bajetta E, **de Braud F**, Mazzaferro V. Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases. *Clin Colorectal Cancer.* 2017 Sep;16(3):e191-e198. doi: 10.1016/j.clcc.2016.09.007.
31. Vernieri C, Milano M, Mennitto A, Maggi C, Ferrari B, Rinaldi L, Mennitto R, Stefanetti C, Re B, Mariani G, Bianchi G, Capri G, **de Braud F**. Antitumor activity and safety profile of weekly carboplatin plus paclitaxel in metastatic breast cancer: a ten-year, monocentric, retrospective study. *Breast Cancer Res Treat.* 2017 Sep;165(2):365-373. doi: 10.1007/s10549-017-4336-z.
32. Berenato R, Morano F, Pietrantonio F, Cotsoglou C, Caporale M, Infante G, Pellegrinelli A, Alessi A, Battiston C, Coppa J, Padovano B, Mennitto A, Niger M, Fucà G, Lazzati S, Greco G, Delconte G, **de Braud F**, Mazzaferro V, Di Bartolomeo M. Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. *Oncology.* 2017 Sep 8. doi: 10.1159/000479154.
33. Cremolini C, Pietrantonio F, Tomasello G, Dadduzio V, Moretto R, Morano F, Schirripa M, Antoniotti C, Fucà G, Bergamo F, Rossini D, Nichetti F, Ziampiri S, Ghidini M, Marmorino F, Prisciandaro M, Falcone A, **De Braud F**, Loupakis F, Lonardi S. Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. *ESMO Open.* 2017 Aug 10;2(3):e000241. doi: 10.1136/esmoopen-2017-000241. eCollection 2017.
34. Pusceddu S, Prinzi N, Lo Russo G, Femia D, Milione M, Perrone F, Tamborini E, Concas L, Pulice I, Vernieri C, Corti F, Buzzoni R, **de Braud F**. Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. *Future Oncol.* 2017 Aug;13(19):1677-1683. doi: 10.2217/fon-2017-0132.

35. Milione M, Ardini E, Christiansen J, Valtorta E, Veronese S, Bosotti R, Pellegrinelli A, Testi A, Pietrantonio F, Fucà G, Wei G, Murphy D, Siena S, Isacchi A, **De Braud F**. Identification and characterization of a novel *SCYL3-NTRK1* rearrangement in a colorectal cancer patient. *Oncotarget*. 2017 Jul 24;8(33):55353-55360. doi: 0.18632/oncotarget.19512. eCollection 2017 Aug 15
36. Berardi R, Torniai M, Pusceddu S, Spada F, Ibrahim T, Brizzi MP, Antonuzzo L, Ferolla P, Panzuto F, Silvestris N, Partelli S, Ferretti B, Freddari F, Gucciardino C, Testa E, Concas L, Murgioni S, Bongiovanni A, Zichi C, Riva N, Rinzivillo M, Brunetti O, Giustini L, Di Costanzo F, Delle Fave G, Fazio N, **De Braud F**, Falconi M, Cascinu S. Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. *Cancer Med*. 2017 Jul;6(7):1493-1499. doi: 10.1002/cam4.1028.
37. Nichetti F, Lobefaro R, Pagani F, Randon G, Corti F, **de Braud F**, Celio L, Platania M. Systemic strategy at the patient's service: a congress report on supportive care in oncology. *Tumori*. 2017 Jul 27:0. doi: 10.5301/TJ.2017.17342.
38. Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, **de Braud F**, Bardelli A, Pietrantonio F, Di Nicolantonio F Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.. *Br J Cancer*. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196.
39. Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Santis MC, Lozza L, **de Braud F**, Di Cosimo S. Complete remission in metastatic breast cancer: expecting the unexpected-results of a cross-sectional study. *Breast Cancer*. 2017 Jul;24(4):635-641. doi: 10.1007/s12282-017-0751-6.
40. Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, **de Braud F**, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol*. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176
41. Pusceddu S, Buzzoni R, **de Braud F**. The underestimated role of somatostatin analogs in the NETTER-1 trial. *Future Oncol*. 2017 Jun;13(15):1287-1289. doi: 10.2217/fon-2017-0130. PMID:28492350
42. Agresti R, Sandri M, Gennaro M, Bianchi G, Maugeri I, Rampa M, Capri G, Carcangiu ML, Trecate G, Riggio E, Lozza L, **de Braud F**. Evaluation of Local Oncologic Safety in Nipple-Areola Complex-sparing Mastectomy After Primary Chemotherapy: A Propensity Score-matched Study. *Clin Breast Cancer*. 2017 Jun;17(3):219-231. doi: 10.1016/j.clbc.2016.12.003. Epub 2016 Dec 24.PMID: 28087389
43. Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J, Bauer TM, Farago AF, Wheler JJ, Liu SV, Doebele R, Giannetta L, Cerea G, Marrapese G, Schirru M, Amatu A, Bencardino K, Palmeri L, Sartore-Bianchi A, Vanzulli A, Cresta S, Damian S, Duca M, Ardini E, Li G, Christiansen J, Kowalski K, Johnson AD, Patel R, Luo D, Chow-Maneval E, Hornby Z, Multani PS, Shaw AT, **De Braud FG**. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). *Cancer Discov*. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237.PMID:28183697

44. Di Salvatore M, Pietrantonio F, Orlandi A, Del Re M, Berenato R, Rossi E, Caporale M, Guarino D, Martinetti A, Basso M, Mennitto R, Santonocito C, Mennitto A, Schinzari G, Bossi I, Capoluongo E, Danesi R, **de Braud F**, Barone C. IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. *Oncotarget*. 2017 Mar 7;8(10):16887-16898. doi: 10.18632/oncotarget.14810. PMID:28129643
45. Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, **de Braud F**, Garassino MC. Concomitant *EML4-ALK* rearrangement and *EGFR* mutation in non-small cell lung cancer patients: a literature review of 100 cases *Oncotarget*. 2017 Apr 26;8(35):59889-59900. doi: 10.18632/oncotarget.17431. eCollection 2017 Aug 29. **Review**.
46. Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Porcu L, **De Braud F**, Porta C, Procopio G. Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents. *Oncology*. 2017;92(5):269-275. doi: 10.1159/000455970.
47. Petrelli F, Berenato R, Turati L, Mennitto A, Steccanella F, Caporale M, Dallera P, **de Braud F**, Pezzica E, Di Bartolomeo M, Sgroi G, Mazzaferro V, Pietrantonio F, Barni S. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. *J Gastrointest Oncol*. 2017 Feb;8(1):148-163. doi: 10.21037/jgo.2017.01.10.
48. Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomatà C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, **De Braud F**, Di Nicolantonio F, Barault L, Siena S. Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. *Eur J Cancer*. 2017 Jan;71:43-50. doi: 10.1016/j.ejca.2016.10.032.
49. Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albrecht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, **de Braud F**, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P. The European Cancer Patient's Bill of Rights, update and implementation 2016. *ESMO Open*. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. **Review**
50. Gevorgyan A, Bregni G, Galli G, Zanardi E, **de Braud F**, Di Cosimo S. HER2-Positive Neuroendocrine Breast Cancer: Case Report and Review of Literature. *Breast Care (Basel)*. 2016 Dec;11(6):424-426. doi: 10.1159/000453572.
51. Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, **de Braud F**, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. *Int J Cancer*. 2016 Dec 15;139(12):2859-2864. doi: 10.1002/ijc.30408

52. Vernieri C, Casola S, Foiani M, Pietrantonio F, **de Braud F**, Longo V. Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions. *Cancer Discov.* 2016 Dec;6(12):1315-1333. Review.
53. Petrelli F, Barni S, Bregni G, **de Braud F**, Di Cosimo S.. Platinum salts in advanced breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Breast Cancer Res Treat.* 2016 Dec;160(3):425-437. doi: 10.1007/s10549-016-4025-3. Review
54. Pietrantonio F, Perrone F, Mennitto A, Gleeson EM, Milione M, Tamborini E, Busico A, Settanni G, Berenato R, Caporale M, Morano F, Bossi I, Pellegrinelli A, Di Bartolomeo M, **de Braud F**, Baratti D, Bowne WB, Kusamura S, Deraco M. Toward the molecular dissection of peritoneal pseudomyxoma. *Ann Oncol.* 2016 Nov;27(11):2097-2103.
55. Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E, Pillai RN, Ott PA, **de Braud F**, Morse M, Le DT, Jaeger D, Chan E, Harbison C, Lin CS, Tschaika M, Azrilevich A, Rosenberg JE. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. *Lancet Oncol.* 2016 Nov;17(11):1590-1598. doi: 10.1016/S1470-2045(16)30496-X.
56. Cavalieri S, Di Guardo L, Cimminiello C, Bono A, Tolomio E, Colombetti A, Valeri B, Di Tolla G, **de Braud F**, Del Vecchio M. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience. *Tumori.* 2016 Oct 13;102(5):501-507. doi: 10.5301/tj.5000539.
57. Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, **de Braud F**, Garassino MC. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. *Tumour Biol.* 2016 Oct;37(10):12991-13003. Review
58. Verzoni E, Grassi P, Ratta R, Niger M, **De Braud F**, Valdagni R, Procopio G. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. *Ther Adv Med Oncol.* 2016 Sep;8(5):323-30. doi: 10.1177/1758834016656493
59. D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, **De Braud F**, Di Leva G, Tripodo C, Iorio MV. miR-9 and miR-200 Regulate PDGFR $\beta$ -Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. *Cancer Res.* 2016 Sep 15;76(18):5562-72. doi: 10.1158/0008-5472.CAN-16-0140.
60. Vernieri C, Femia D, Pusceddu S, Capella C, Rosai J, Calareso G, Concas L, Prinzi N, Lo Russo G, **de Braud F**, Buzzoni R. Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up. *Case Rep Oncol.* 2016 Aug 17;9(2):432-439. eCollection 2016 May-Aug.
61. Grassi P, Verzoni E, Ratta R, Mennitto A, **de Braud F**, Procopio G. Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy. *Drug Des Devel Ther.* 2016 Jul 5;10:2167-72. doi: 10.2147/DDDT.S104225. eCollection 2016. Review.
62. D'Ippolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C, Orlandi R, Gualeni AV, Gloghini A, Rossini A, Cresta S, Tessari A, **de Braud F**, Di Leva G, Tripodo C, Iorio MV. MiR-9 and miR-200 regulate PDGFR $\beta$ -mediated endothelial differentiation of tumor cells in triple negative breast cancer. *Cancer Res.* 2016 Jul 11. pii: canres.0140.2016.

63. Moretto R, Cremolini C, Rossini D, Pietrantonio F, Battaglin F, Mennitto A, Bergamo F, Loupakis F, Marmorino F, Berenato R, Marsico VA, Caporale M, Antoniotti C, Masi G, Salvatore L, Borelli B, Fontanini G, Lonardi S, **De Braud F**, Falcone A. Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. *Oncologist*. 2016 Jul 5. pii: theoncologist.2016-0084.
64. Ratta R, Zappasodi R, Raggi D, Grassi P, Verzoni E, Necchi A, Di Nicola M, Salvioni R, **de Braud F**, Procopio G. Immunotherapy advances in uro-genital malignancies. *Crit Rev Oncol Hematol*. 2016 Jun 17. pii: S1040-8428(16)30145-7. doi: 10.1016/j.critrevonc.2016.06.012 Review.
65. Pusceddu S, Femia D, Lo Russo G, Ortolani S, Milione M, Maccauro M, Vernieri C, Prinzi N, Concas L, Leuzzi L, **De Braud F**, Buzzoni R. Update on medical treatment of small intestinal neuroendocrine tumors. *Expert Rev Anticancer Ther*. 2016 Jul 13:1-8.
66. Simonelli M, Zucali P, Santoro A, Thomas MB, **de Braud FG**, Borghaei H, Berlin J, Denlinger CS, Noberasco C, Rimassa L, Kim TY, English PA, Abbattista A, Gallo Stampino C, Carpentieri M, Williams JA. Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. *Ann Oncol*. 2016 Sep;27(9):1782-7. doi: 10.1093/annonc/mdw240.
67. Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, **de Braud F**, Di Nicolantonio F. MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer. *Cancer Discov*. 2016 Jun 20. pii: CD-16-0297. PMID: 27325282
68. Gelsomino F, Castellani MR, Marchianò A, Duca M, Mariani P, Aliberti G, Maccauro M, Duranti L, Capri G, **de Braud FG**, Bianchi GV. Pitfalls in oncology: a unique case of thoracic splenosis mimicking malignancy in a patient with resected breast cancer. *J Thorac Dis*. 2016 Jun;8(6):E403-7. doi: 10.21037/jtd.2016.04.54. PMID: 27293867
69. Procopio G, Ratta R, **de Braud F**. Improved quality of life is the way to longer life. *Lancet Oncol*. 2016 Jul;17(7):862-3. doi: 10.1016/S1470-2045(16)30158-9. PMID: 27283861
70. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, **de Braud F**, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol*. 2016 Jul;17(7):883-95. doi: 10.1016/S1470-2045(16)30098-5. PMID: 27269741
71. Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, **de Braud F**, Di Cosimo S. Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. *Tumori*. 2016 May 10:0. doi: 10.5301/tj.5000515. PMID: 27174629
72. Pietrantonio F, Berenato R, Maggi C, Caporale M, Milione M, Perrone F, Tamborini E, Baratti D, Kusamura S, Mariani L, Nigam M, Mennitto A, Gloghini A, Bossi I, Settanni G, Busico A, Bagnoli PF, Di Bartolomeo M, Deraco M, **de Braud F**. GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. *J Transl Med*. 2016 May 6;14(1):125. doi: 10.1186/s12967-016-0877-x.PMID:27154293



73. Lo Russo G, Macerelli M, Platania M, Zilembo N, Vitali M, Signorelli D, Proto C, Ganzinelli M, Gallucci R, Agustoni F, Fasola G, **de Braud F**, Garassino MC. SMALL-CELL LUNG CANCER: CLINICAL MANAGEMENT AND UNMET NEEDS, New perspectives for an old problem. *Curr Drug Targets*. 2016 May 2. PMID:27138756
74. Mazzaferro V, Sposito C, Coppa J, Miceli R, Bhoori S, Bongini M, Camerini T, Milione M, Regalia E, Spreafico C, Gangeri L, Buzzoni R, **de Braud FG**, De Feo T, Mariani L. The Long-term Benefit of Liver Transplantation for Hepatic Metastases from Neuroendocrine Tumors. *Am J Transplant*. 2016 May 1. doi: 10.1111/ajt.13831.
75. Di Cosimo S, Bregni G, Daidone MG, Cinquini M, **de Braud F**, Torri V. Waiting for Godot: Predictive factors for adjuvant treatment of patients with luminal breast cancer. *Breast*. 2016 Apr 22. pii: S0960-9776(16)00017-5. doi: 10.1016/j.breast.2016.02.002.
76. Falanga A, Santoro A, Labianca R, **De Braud F**, Gasparini G, D'Alessio A, Barni S, Iacoviello L; HYPERCAN Study Group. Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. *Thromb Res*. 2016 Apr;140 Suppl 1:S55-9. doi: 10.1016/S0049-3848(16)30099-8.
77. Grassi P, Doucet L, Giglione P, Grünwald V, Melichar B, Galli L, De Giorgi U, Sabbatini R, Ortega C, Santoni M, Bamias A, Verzoni E, Derosa L, Studentova H, Pacifici M, Coppa J, Mazzaferro V, **de Braud F**, Porta C, Escudier B, Procopio G. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis. *PLoS One*. 2016 Apr 11;11(4):e0151662. doi: 10.1371/journal.pone.0151662. eCollection 2016
78. Pusceddu S, **De Braud F**, Lo Russo G, Concas L, Femia D, Vernieri C, Indini A, Formisano B, Buzzoni R. How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies. *Oncotarget*. 2016 Apr 5. doi: 10.18632/oncotarget.8601. Review
79. Pelosi G, Pellegrinelli A, Fabbri A, Tamborini E, Perrone F, Settanni G, Busico A, Piccioni B, Testi MA, Militti L, Maisonneuve P, Valeri B, Sonzogni A, Proto C, Garassino M, **De Braud F**, Pastorino U. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. *Virchows Arch*. 2016 Apr 7.
80. Falvella FS, Cremolini C, Miceli R, Nichetti F, Cheli S, Antoniotti C, Infante G, Martinetti A, Marmorino F, Sottotetti E, Berenato R, Caporale M, Colombo A, **de Braud F**, Di Bartolomeo M, Clementi E, Loupakis F, Pietrantonio F. Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. *Pharmacogenomics J*. 2016 Mar 22. doi: 10.1038/tpj.2016.22.
81. Stathis A, Zucca E, Bekradda M, Gomez-Roca C, Delord JP, de La Motte Rouge T, Uro-Coste E, **de Braud F**, Pelosi G, French CA. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628. *Cancer Discov*. 2016 May;6(5):492-500.
82. Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, **de Braud F**, Garassino MC. Treatment of lung large cell neuroendocrine carcinoma. *Tumour Biol*. 2016 Mar 4.

83. Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, **de Braud F**, Garassino MC. Diagnosis and management of typical and atypical lung carcinoids. *Crit Rev Oncol Hematol*. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Review.
84. Giampieri R, Caporale M, Pietrantonio F, **De Braud F**, Negri FV, Giuliani F, Pusceddu V, Demurtas L, Restivo A, Fontanella C, Aprile G, Cascinu S, Scartozzi M. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded? *Crit Rev Oncol Hematol*. 2016 Apr;100:99-106. doi: 10.1016/j.critrevonc.2016.02.005. Review.
85. Pusceddu S, Buzzoni R, Vernieri C, Concas L, Marceglia S, Giacomelli L, Milione M, Leuzzi L, Femia D, Formisano B, Mazzaferro V, **de Braud F**. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes. *Future Oncol*. 2016 May;12(10):1251-60. doi: 10.2217/fon-2015-0077.
86. Necchi A, Lo Vullo S, Mariani L, Raggi D, Giannatempo P, Calareso G, Togliardi E, Crippa F, Di Genova N, Perrone F, Colecchia M, Paolini B, Pelosi G, Nicolai N, Procopio G, Salvioni R, **De Braud FG**. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. *Invest New Drugs*. 2016 Apr;34(2):236-42. doi: 10.1007/s10637-016-0328-9.
87. Pelosi G, Perrone F, Tamborini E, Fabbri A, Testi MA, Busico A, Settanni G, Picciani B, Bovio E, Sonzogni A, Valeri B, Garassino M, **De Braud F**, Pastorino U. Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. *Virchows Arch*. 2016 Apr;468(4):451-61. doi: 10.1007/s00428-016-1906-0.
88. Indini A, Di Nicola M, Del Vecchio M, **De Braud F**. Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. *J Clin Oncol*. 2016 Jan 19. pii: JCO650028. [Epub ahead of print] No abstract available. PMID:26786928
89. Fazio N, Biffi R, Maibach R, Hayoz S, Thierstein S, Brauchli P, Bernhard J, Stupp R, Andreoni B, Renne G, Crosta C, Morant R, Chiappa A, Luca F, Zampino MG, Huber O, Goldhirsch A, **de Braud F**, Roth AD; Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (IEO), Milan, Italy. Pre-operative versus post-operative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. *Ann Oncol*. 2015 Dec 27. pii: mdv620.
90. Vergani E, Di Guardo L, Dugo M, Rigoletto S, Tragni G, Ruggeri R, Perrone F, Tamborini E, Gloghini A, Arienti F, Vergani B, Deho P, De Cecco L, Vallacchi V, Frati P, Shahaj E, Villa A, Santinami M, **De Braud F**, Rivoltini L, Rodolfo M. Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b. *Oncotarget*. 2015 Dec 14. doi: 10.18632/oncotarget.6599.
91. Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, **de Braud F**, Mortarini R, Anichini A. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. *Oncotarget*. 2015 Dec 14. doi: 10.18632/oncotarget.6600.
92. Goff LW, Cohen RB, Berlin J, **De Braud FG**, Lyshchik A, Noberasco C, Bertolini F, Carpentieri M, Gallo Stampino C, Abbattista A, Wang E, Borghaei H. A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. *Clin Cancer Res*. 2015 Dec 11. pii: clincanres.1622.2015.

93. Zanardi E, Bregni G, **de Braud F**, Di Cosimo S. Better Together: Targeted Combination Therapies in Breast Cancer. *Semin Oncol.* 2015 Dec;42(6):887-95. doi: 10.1053/j.seminoncol.2015.09.029. Epub 2015 Sep 24. Review
94. Catania C, Feroce I, Barile M, Goldhirsch A, De Pas T, **de Braud F**, Boselli S, Adamoli L, Radice D, Rossi A, Spitaleri G, Noberasco C, Bonanni B. Improved health perception after genetic counselling for women at high risk of breast and/or ovarian cancer: construction of new questionnaires-an Italian exploratory study. *J Cancer Res Clin Oncol.* 2015 Nov 17
95. Pietrantonio F, **de Braud F**, Milione M, Maggi C, Iacovelli R, Dotti KF, Perrone F, Tamborini E, Caporale M, Berenato R, Leone G, Pellegrinelli A, Bossi I, Festinese F, Federici S, Di Bartolomeo M. Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer. *Target Oncol.* 2015 Nov 4
96. Iacovelli R, Pietrantonio F, Maggi C, **de Braud F**, Di Bartolomeo M. Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials. *Crit Rev Oncol Hematol.* 2015 Oct 9. pii: S1040-8428(15)30043-3. doi: 10.1016/j.critrevonc.2015.09.002.
97. Signorelli D, Macerelli M, Proto C, Vitali M, Cona MS, Agustoni F, Zilembo N, Platania M, Trama A, Gallucci R, Ganzinelli M, Pelosi G, Pastorino U, **de Braud F**, Garassino MC, Lo Russo G. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy? *Tumori.* 2015 Oct 15;0(0):0. doi: 10.5301/tj.5000436.
98. Pietrantonio F, Cremolini C, Aprile G, Lonardi S, Orlandi A, Mennitto A, Berenato R, Antoniotti C, Casagrande M, Marsico V, Marmorino F, Cardellino GG, Bergamo F, Tomasello G, Formica V, Longarini R, Giommoni E, Caporale M, Di Bartolomeo M, Loupakis F, **de Braud F**. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. *Oncologist.* 2015 Nov;20(11):1261-5. doi: 10.1634/theoncologist.2015-0171
99. Pelosi G, Fabbri A, Tamborini E, Perrone F, Testi AM, Settanni G, Busico A, Centonze G, Braidotti P, Bulfamante G, **De Braud F**, Garassino M, Pastorino U. Challenging Lung Carcinoma with Coexistent  $\Delta$ Np63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. *J Thorac Oncol.* 2015 Oct;10(10):1500-2. doi: 10.1097/JTO.0000000000000553.
100. **de Braud F**, Cascinu S, Spitaleri G, Pilz K, Clementi L, Liu D, Sikken P, De Pas T. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. *Ann Oncol.* 2015 Nov;26(11):2341-6. doi: 10.1093/annonc/mdv354.
101. Zappasodi R, **de Braud F**, Di Nicola M. Lymphoma Immunotherapy: Current Status. *Front Immunol.* 2015 Sep 1;6:448. doi: 10.3389/fimmu.2015.00448. eCollection 2015. Review. PMID: 26388871
102. Pinciroli P, Won H, Iyer G, Canevari S, Colecchia M, Giannatempo P, Raggi D, Pierotti MA, **De Braud FG**, Solit DB, Rosenberg JE, Berger MF, Necchi A. Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. *Clin Genitourin Cancer.* 2015 Aug 7. pii: S1558-7673(15)00190-1. doi: 10.1016/j.clgc.2015.07.017

103. Bregni G, Galli G, Gevorgyan A, **de Braud F**, Di Cosimo S. Trastuzumab cardiac toxicity: a problem we put our heart into. *Tumori*. 2015 Aug 3;0(0):0. doi: 10.5301/tj.5000393.
104. Pietrantonio F, Aprile G, Rimassa L, Franco P, Lonardi S, Cremolini C, Biondani P, Sbicego EL, Pasqualetti F, Tomasello G, Niger M, Casagrande M, Ghidini M, Muni R, Montrone S, Bergamo F, Berenato R, Fontanella C, Bozzarelli S, Moretto R, Battaglin F, Di Bartolomeo M, **de Braud F**, Miceli R. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer. *Radiother Oncol*. 2015 Sep 4. pii: S0167-8140(15)00448-X. doi: 10.1016/j.radonc.2015.08.023
105. Schmoll HJ, Tabernero J, Maroun J, **de Braud F**, Price T, Van Cutsem E, Hill M, Hoersch S, Rittweger K, Haller DG. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. *J Clin Oncol*. 2015 Nov 10;33(32):3733-40. doi: 10.1200/JCO.2015.60.9107.
106. Pelosi G, Fabbri A, Papotti M, Rossi G, Cavazza A, Righi L, Tamborini E, Perrone F, Settanni G, Busico A, Testi MA, Maisonneuve P, **De Braud F**, Garassino M, Valeri B, Sonzogni A, Pastorino U. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. *J Thorac Oncol*. 2015 Nov;10(11):1560-9. doi: 10.1097/JTO.0000000000000658.
107. Celio L, Bonizzoni E, **De Braud F**, Agustoni F, Aapro M. Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. *Support Care Cancer*. 2015 Aug 6.
108. Pusceddu S, **De Braud F**, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. *Future Oncol*. 2015;11(13):1947-59. doi: 10.2217/fon.15.86.
109. Zanardi E, Verzoni E, Grassi P, Necchi A, Giannatempo P, Raggi D, **De Braud F**, Procopio G. Clinical experience with temsirolimus in the treatment of advanced renal cell carcinoma. *Ther Adv Urol*. 2015 Jun;7(3):152-61. doi: 10.1177/1756287215574457. Review.
110. PMID:26161146
111. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, **de Braud F**, Loupakis F, Pietrantonio F. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. *Ann Oncol*. 2015 Oct;26(10):2092-7. doi: 10.1093/annonc/mdv290.
112. Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomatà C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, **De Braud F**, Rudà R, Soffiotti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. *Ann Oncol*. 2015 Sep;26(9):1994-9. doi: 10.1093/annonc/mdv272

113. Pietrantonio F, Cremolini C, Petrelli F, Di Bartolomeo M, Loupakis F, Maggi C, Antoniotti C, **de Braud F**, Falcone A, Iacovelli R. First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. *Crit Rev Oncol Hematol*. 2015 Oct;96(1):156-66. doi: 10.1016/j.critrevonc.2015.05.016.
114. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, **de Braud F**, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Swann S, Legos JJ, Jin F, Mookerjee B, Flaherty K. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet*. 2015 Aug 1;386(9992):444-51. doi: 10.1016/S0140-6736(15)60898-4.
115. Pietrantonio F, Mazzaferro V, Miceli R, Cotsoglou C, Melotti F, Fanetti G, Perrone F, Biondani P, Muscarà C, Di Bartolomeo M, Coppa J, Maggi C, Milione M, Tamborini E, **de Braud F**. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. *Med Oncol*. 2015 Jul;32(7):182. doi: 10.1007/s12032-015-0638-3.
116. Raggi D, Mariani L, Giannatempo P, Lo Vullo S, Giardiello D, Nicolai N, Piva L, Biondi D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Calareso G, Magni M, Di Nicola M, Verzoni E, Grassi P, Procopio G, **De Braud F**, Pizzocaro G, Salvioni R, Necchi A. Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. *Urol Oncol*. 2015 Jul;33(7):332.e19-24. doi: 10.1016/j.urolonc.2015.04.008.
117. Pietrantonio F, Orlandi A, Inno A, Da Prat V, Spada D, Iaculli A, Di Bartolomeo M, Morosi C, **de Braud F**. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians. *Crit Rev Oncol Hematol*. 2015 Sep;95(3):272-81. doi: 10.1016/j.critrevonc.2015.04.008. Epub 2015 Apr 25. Review.
118. Panzuto F, Rinzivillo M, Fazio N, **de Braud F**, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Carteni G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-world study of everolimus in advanced progressive neuroendocrine tumors. *Oncologist*. 2015 May;20(5):570. doi: 10.1634/theoncologist.2014-0037erratum.
119. Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Nigam M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, **de Braud F**, Clementi E, Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. *Int J Mol Sci*. 2015 Apr 21;16(4):8884-95. doi: 10.3390/ijms16048884. Review.
120. Di Bartolomeo M, Pietrantonio F, Pellegrinelli A, Martinetti A, Mariani L, Daidone MG, Bajetta E, Pelosi G, **de Braud F**, Floriani I, Miceli R. Osteopontin, E-cadherin, and  $\beta$ -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. *Gastric Cancer*. 2015 Apr 11. PMID: 25862567

121. Grassi P, Verzoni E, Porcu L, Iacovelli R, **de Braud F**, Procopio G. Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib. *Ther Adv Urol*. 2015 Apr;7(2):59-68. doi:10.1177/1756287215571809.
122. Petrelli F, Pietrantonio F, Cremolini C, Di Bartolomeo M, Coinu A, Lonati V, **de Braud F**, Barni S. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: A systematic review and pooled-analysis. *Eur J Cancer*. 2015 Mar 17. pii: S0959-8049(15)00211-7. doi: 10.1016/j.ejca.2015.02.011.
123. Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, **de Braud F**, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, Flaherty KT, Nathan P, Ribas A, Robert C, Casey M, DeMarini DJ, Irani JG, Aktan G, Long GV. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. *Eur J Cancer*. 2015 Mar 17. pii: S0959-8049(15)00220-8. doi: 10.1016/j.ejca.2015.03.004.
124. Falvella FS, Cheli S, Martinetti A, Mazzali C, Iacovelli R, Maggi C, Gariboldi M, Pierotti MA, Di Bartolomeo M, Sottotetti E, Mennitto R, Bossi I, **de Braud F**, Clementi E, Pietrantonio F. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. *Br J Clin Pharmacol*. 2015 Mar 17. doi: 10.1111/bcp.12631.
125. Lucibello M, Adanti S, Antelmi E, Dezi D, Ciafrè S, Carcangiu ML, Zonfrillo M, Nicotera G, Sica L, **De Braud F**, Pierimarchi P. Phospho-TCIP as a therapeutic target of Dihydroartemisinin for aggressive breast cancer cells. *Oncotarget*. 2015 Mar 10;6(7):5275-5291.
126. Di Cosimo S, Bianchi GV, Bregni G, **de Braud F**. Prognosis of women with early breast cancer and PIK3CA mutations. *Breast*. 2015 Mar 12. pii: S0960-9776(15)00043-0. doi: 10.1016/j.breast.2015.02.028. [
127. Baratti D, Kusamura S, Maggi C, **de Braud F**, Deraco M, Di Bartolomeo M, Pietrantonio F. In reply. *Oncologist*. 2015 Mar;20(3):e5. doi: 10.1634/theoncologist.2014-423.
128. Dugo M, Nicolini G, Tragni G, Bersani I, Tomassetti A, Colonna V, Del Vecchio M, **De Braud F**, Canevari S, Anichini A, Sensi M. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. *Oncotarget*. 2015 Mar 10;6(7):5118-5133
129. Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, **de Braud F**, Daidone MG, Cappelletti V. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. *Int J Cancer*. 2015 Feb 20. doi: 10.1002/ijc.29493.
130. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, **de Braud F**, Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis. *Eur J Cancer*. 2015 Mar;51(5):587-594. doi: 10.1016/j.ejca.2015.01.054.
131. Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri E, Maugeri I, Rampa M, Carcangiu ML, Trecate G, Pascali C, Bogni A,

- Martelli G, **de Braud F**. 18F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study. *Eur J Nucl Med Mol Imaging*. 2015 Feb 12. 10.1007/s00259-015-2995-8
132. Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, **de Braud F**, Torri V, Di Cosimo S. Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies. *Clin Transl Oncol*. 2015 Jan 21. DOI 10.1007/s12094-015-1274-2
133. Di Bartolomeo M, Maggi C, Ricchini F, Pietrantonio F, Iacovelli R, de Braud F, Inno A. Bevacizumab treatment in the elderly patient with metastatic colorectal cancer. *Clin Interv Aging*. 2015 Jan 5;10:127-33. doi: 10.2147/CIA.S54675. eCollection 2015. PMID:25584021
134. Zappasodi R, Ruggiero G, Guarnotta C, Tortoreto M, Tringali C, Cavanè A, Cabras AD, Castagnoli L, Venerando B, Zaffaroni N, Gianni AM, **De Braud F**, Tripodo C, Pupa SM, Di Nicola M. HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. *Blood* 2015 Mar 12;125(11):1768-71. doi: 10.1182/blood-2014-07-590034. Epub 2015 Jan 8.
135. Catania C, Maur M, Berardi R, Rocca A, Di Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, **de Braud F**. The tumour-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumours and expansion into patients with metastatic breast cancer. *Cell Adh Migr*. 2015 Jan 2;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.
136. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators. Collaborators First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014 Dec 4;371(23):2167-77. doi: 10.1056/NEJMoa1408440.
137. Iacovelli R, Pietrantonio F, Palazzo A, Maggi C, Ricchini F, **de Braud F**, Di Bartolomeo M. Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials. *Br J Clin Pharmacol*. 2014 Dec;78(6):1228-37. doi: 10.1111/bcp.12449
138. Inno A, Fanetti G, Di Bartolomeo M, Gori S, Maggi C, Cirillo M, Iacovelli R, Nichetti F, Martinetti A, **de Braud F**, Bossi I, Pietrantonio F. Role of MGMT as biomarker in colorectal cancer. *World J Clin Cases*. 2014 Dec 16;2(12):835-9. doi: 10.12998/wjcc.v2.i12.835. Review
139. Pietrantonio F, Iacovelli R, Di Bartolomeo M, **de Braud F**. FOLFIRI with cetuximab or bevacizumab: FIRE-3. *Lancet Oncol*. 2014 Dec;15(13):e581. doi: 10.1016/S1470-2045(14)70397-3.
140. Iacovelli R, Verzoni E, Grassi P, Farcomeni A, **de Braud F**, Procopio G. Rationale and protocol of SOAP: a phase II study to evaluate the efficacy of sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma. *Tumori*. 2014 Nov-Dec;100(6):282e-5e. doi: 10.1700/1778.19296.PMID: 25688511
141. Pusceddu S, **de Braud F**, Concas L, Bregant C, Leuzzi L, Formisano B, Buzzoni R. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study

to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. *Tumori*. 2014 Nov-Dec;100(6):286e-9e. doi: 10.1700/1778.19298.PMID:25688512

142. Serpico D, Trama A, Haspinger ER, Agustoni F, Botta L, Berardi R, Palmieri G, Zucali P, Gallucci R, Brogginì M, Gatta G, Pastorino U, Pelosi G, **de Braud F**, Garassino MC; on behalf of TYME (TYmic MalignanciEs) Collaborative Group. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. *Ann Oncol*. 2014 Nov 19. pii: mdu527. [Epub ahead of print] Review
143. Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, Galli G, **De Braud F**, Saravia D, Salvioni R. Time from Nephrectomy as a Prognostic Factor in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapies: Overall Results from a Large Cohort of Patients. *Oncology*. 2014 Nov 4;88(3):133-138.
144. Iacovelli R, Pietrantonio F, Farcomeni A, Maggi C, Palazzo A, Ricchini F, **de Braud F**, Di Bartolomeo M. Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies. *PLoS One*. 2014 Sep 30;9(9):e108940. doi: 10.1371/journal.pone.0108940. eCollection 2014
145. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, **de Braud F**, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JB, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin AM, Le N, Patel K, Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med*. 2014 Nov 13;371(20):1877-88. doi: 10.1056/NEJMoa1406037.
146. Iacovelli R, Santoni M, **de Braud F**, Cascinu S, Procopio G. Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancer. *Expert Rev Anticancer Ther*. 2014 Aug 27:1-3
147. Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, **de Braud F**, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. *Cancers (Basel)*. 2014 Aug 29;6(3):1753-68. doi: 10.3390/cancers6031753
148. Giannatempo P, Greco T, Mariani L, Nicolai N, Tana S, Farè E, Raggi D, Piva L, Catanzaro M, BIASONI D, Torelli T, Stagni S, Avuzzi B, Maffezzini M, Landoni G, **De Braud F**, Gianni AM, Sonpavde G, Salvioni R, Necchi A. Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes† *Ann Oncol*. 2014 Sep 11. pii: mdu447. [Epub ahead of print] Review.
149. Verzoni E, Puscèddu S, Buzzoni R, Garanzini E, Damato A, Biondani P, Testa I, Grassi P, Bajetta E, **de Braud F**, Procopio G. Safety profile and treatment response of everolimus in different solid tumors: an observational study. *Future Oncol*. 2014;10(9):1611-7. doi: 10.2217/fon.14.31
150. Iacovelli R, Santoni M, Verzoni E, Grassi P, Testa I, de Braud F, Cascinu S, Procopio G. Everolimus and Temsirolimus Are Not the Same Second-Line in Metastatic Renal Cell Carcinoma. A Systematic Review and Meta-Analysis of Literature Data. *Clin Genitourin Cancer*. 2014 Aug 2. pii: S1558-7673(14)00153-0. doi: 10.1016/j.clgc.2014.07.006
151. Necchi A, Giannatempo P, Paolini B, Lo Vullo S, Marongiu M, Farè E, Raggi D, Nicolai N, Piva L, Catanzaro M, BIASONI D, Torelli T, Stagni S, Maffezzini M, Gianni AM,



**De Braud F**, Mariani L, Sonpavde G, Colecchia M, Salvioni R. Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. *Clin Genitourin Cancer*. 2014 Aug 8. pii: S1558-7673(14)00174-8. doi: 10.1016/j.clgc.2014.08.002

152. Pietrantonio F, Maggi C, Di Bartolomeo M, Facciorusso MG, Perrone F, Testi A, Iacovelli R, Miceli R, Bossi I, Leone G, Milione M, Pelosi G, **de Braud F**. Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status. *PLoS One*. 2014 Apr 1;9(4):e92147. doi: 10.1371/journal.pone.0092147. eCollection 2014.
153. Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, **de Braud F**, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study. *Psychooncology*. 2014 Mar;23(3):322-9. doi: 10.1002/pon.3424. Epub 2013 Oct 10. PMID: 24123459
154. Verzoni E, Grassi P, Testa I, Iacovelli R, Biondani P, Garanzini E, **De Braud F**, Procopio G. Targeted treatments in advanced renal cell carcinoma: focus on axitinib. *Pharmacogenomics Pers Med*. 2014 Mar 27;7:107-116. eCollection 2014. Review. 249.
155. Procopio G, Verzoni E, Biondani P, Grassi P, Testa I, Garanzini E, De Braud F. Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases. *Tumori*. 2014 Jan-Feb;100(1):28e-30e. doi:10.1700/1430.15834.
156. Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, **De Braud F**. PF-03446962, a fully-human monoclonal antibody against transforming growth-factor  $\beta$  (TGF $\beta$ ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. *Invest New Drugs*. 2014 Feb 26. *Invest New Drugs* (2014) 32:555–560 DOI 10.1007/s10637-014-0074-9
157. Platania M, Valeri B, Marchianò A, Calareso G, Agustoni F, Haspinger E, Pusceddu S, Garassino MC, Gelsomino F, **de Braud F**. Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer. *Int J Colorectal Dis*. *Int J Colorectal Dis*. 2015 Mar;30(3):429-30. doi: 10.1007/s00384-014-1993-9. Epub 2014 Aug 21
158. Panzuto F, Rinzivillo M, Fazio N, **de Braud F**, Luppi G, Zatelli MC, Lugli F, Tomassetti P, Riccardi F, Nuzzo C, Brizzi MP, Faggiano A, Zaniboni A, Nobili E, Pastorelli D, Cascinu S, Merlano M, Chiara S, Antonuzzo L, Funaioli C, Spada F, Pusceddu S, Fontana A, Ambrosio MR, Cassano A, Campana D, Carteni G, Appetecchia M, Berruti A, Colao A, Falconi M, Delle Fave G. Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. *Oncologist*. 2014 Aug 12. pii: theoncologist.2014-0037.
159. Procopio G, Verzoni E, **De Braud F**. Butterfly and Renal Cell Cancer: Out of Chaos Comes Order. *J Clin Oncol*. 2014 Jul 28. pii: JCO.2014.56.4757.
160. Pietrantonio F, Maggi C, Fanetti G, Iacovelli R, Di Bartolomeo M, Ricchini F, Deraco M, Perrone F, Baratti D, Kusamura S, Tamborini E, Castano A, Consonni PV, Bossi I, Gavazzi C, Milione M, Pelosi G, **de Braud F**. FOLFOX-4 Chemotherapy for

Patients With Unresectable or Relapsed Peritoneal Pseudomyxoma. *Oncologist*. 2014 Aug;19(8):845-50. doi: 10.1634/theoncologist.2014-0106.

161. Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, Melotti F, Maggi C, Montemurro G, Bossi I, Mariani L, **de Braud F**. TP53 mutations in advanced colorectal cancer: the dark side of the moon. *Oncology*. 2014;86(5-6):289-94. doi: 10.1159/000360088.
162. Pelosi G, Haspinger ER, Bimbatti M, Leone G, Paolini B, Fabbri A, Tamborini E, Perrone F, Testi A, Garassino M, Maisonneuve P, **de Braud F**, Pilotti S, Pastorino U. Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non-Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases. *Int J Surg Pathol*. 2014 Apr;22(2):136-48. doi: 10.1177/1066896913511527.
163. Celio L, de Braud F, Aapro M. Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron? *J Clin Oncol*. 2014 Jul 10;32(20):2185-6. doi: 10.1200/JCO.2014.55.4352.
164. Simbolo M1, Fassan M, Ruzzenente A, Mafficini A, Wood LD, Corbo V, Melisi D, Malleo G, Vicentini C, Malpeli G, Antonello D, Sperandio N, Capelli P, Tomezzoli A, Iacono C, Lawlor RT, Bassi C, Hruban RH, Guglielmi A, Tortora G, **de Braud F**, Scarpa A. Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups. *Oncotarget*. 2014 May 15;5(9):2839-52.
165. Buzzoni R, Pusceddu S, Bajetta E, **De Braud F**, Platania M, Iannacone C, Cantore M, Mambrini A, Bertolini A, Alabiso O, Ciarlo A, Turco C1, Mazzaferro V. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study. *Ann Oncol*. 2014 Aug;25(8):1597-603. doi: 10.1093/annonc/mdu175.
166. Iacovelli R, Verzoni E, **De Braud FM**, Procopio G. Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy? *Cancer Biol Ther*. 2014 May;15(5):486-8. doi: 10.4161/cbt.28161.
167. Biondani P, Verzoni E, Torri V, Porcu L, Grassi P, Testa I, **DE Braud F**, Procopio G. Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. *Anticancer Res*. 2014 May;34(5):2395-8.
168. Toffalorio F, Spitaleri G, Catania C, Dal Zotto L, Noberasco C, Delmonte A, Santarpia M, Vecchio F, Brunelli V, Rampinelli C, Barberis M, Fumagalli C, Zucchetti M, Zangarini M, Diena T, Danesi R, **de Braud F**, De Pas T. Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. *Oncologist*. 2014 Apr;19(4):344-5. doi: 10.1634/theoncologist.2013-0335.
169. Seregini E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, **De Braud F**, Buzzoni R, Milione M, Lorenzoni A, Boggi A, Coliva A, Vullo SL, Bombardieri E. Treatment with tandem [<sup>90</sup>Y]DOTA-TATE and [<sup>177</sup>Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. *Eur J Nucl Med Mol Imaging*. 2014 Feb;41(2):223-30.
170. Procopio G, Testa I, Iacovelli R, Grassi P, Verzoni E, Garanzini E, Colecchia M, Torelli T, **DE Braud F**. Treatment of collecting duct carcinoma: current status and future perspectives. *Anticancer Res*. 2014 Feb;34(2):1027-30.
171. Haspinger ER, Garassino MC, Torri V, Cinquini M, **De Braud F**, Gelsomino F. Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in

First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations? *J Clin Oncol*. 2014 Feb 3.

172. Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, **de Braud** F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG. A Catalyst for Change: The European Cancer Patient's Bill of Rights. *Oncologist*. 2014 Feb 3.
173. Pietrantonio F, Perrone F, **de Braud** F, Castano A, Maggi C, Bossi I, Gevorgyan A, Biondani P, Pacifici M, Busico A, Gariboldi M, Festinese F, Tamborini E, Di Bartolomeo M. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation. *Ann Oncol*. 2014 Feb;25(2):404-8. doi: 10.1093/annonc/mdt547.
174. Di Cosimo S, Serpico D, Porcu L, Molino L, Fanetti G, Torri V, **de Braud** F. Clinical Outcome of HER2-positive Breast Cancer Patients after Failure on Adjuvant Trastuzumab: The Potential of the Time to Relapse. *Clin Oncol (R Coll Radiol)*. 2014 Mar;26(3):174. doi: 10.1016/j.clon.2013.11.028.
175. Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, **De Braud** F, Tiseo M. Targeting the MET gene for the treatment of non-small-cell lung cancer. *Crit Rev Oncol Hematol*. 2014 Feb;89(2):284-99. doi: 10.1016/j.critrevonc.2013.11.006.
176. Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, **De Braud** FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. *Br J Cancer*. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719.
177. Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, **de Braud** F, Garassino MC. Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. *Cancer Treat Rev*. doi:pii: S0305-7372(13)00097-2. 10.1016/j.ctrv.2013.05.005. *Cancer Treat Rev*. 2014 Feb;40(1):197-203. doi: 10.1016/j.ctrv.2013.05.005. Epub 2013 Jul 10.
178. Necchi A, Mariani L, Giannatempo P, Raggi D, Farè E, Nicolai N, Piva L, Biondi D, Catanzaro M, Torelli T, Stagni S, Maffezzini M, Pizzocaro G, **De Braud** FG, Gianni AM, Salvioni R. Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC Methotrexate /Vinblastine /Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. *Clin Genitourin Cancer*. 2013 Nov 21. pii: S1558-7673(13)00293-0. doi: 10.1016/j.clgc.2013.11.022.
179. Iacovelli R, Verzoni E, **De Braud** F, Procopio G. First line treatment of metastatic renal cell carcinoma: Two standards with different toxicity profile. *Cancer Biol Ther*. 2014 Jan 1;15(1):19-21. doi: 10.4161/cbt.27150.
180. Improta G, Pelosi G, Tamborini E, Donia M, Santinami M, **de Braud** F, Frassetto F. Biological insights into BRAF<sup>V600</sup> mutations in melanoma patient: Not mere therapeutic targets. *Oncoimmunology*. 2013 Aug 1;2(8):e25594. Epub 2013 Jul 3. PMID:24179707

181. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, Niknafs N, Guthrie VB, Maitra A, Argani P, Offerhaus GJ, Roa JC, Roberts LR, Gores GJ, Popescu I, Alexandrescu ST, Dima S, Fassan M, Simbolo M, Mafficini A, Capelli P, Lawlor RT, Ruzzenente A, Guglielmi A, Tortora G, **de Braud F**, Scarpa A, Jarnagin W, Klimstra D, Karchin R, Velculescu VE, Hruban RH, Vogelstein B, Kinzler KW, Papadopoulos N, Wood LD. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. *Nat Genet.* 2013 Dec;45(12):1470-3. doi: 10.1038/ng.2813.
182. Verzoni E, **de Braud F**, Fabiani F, Grassi P, Testa I, Procopio G. Patient approach in advanced/metastatic renal cell carcinoma: focus on the elderly population and treatment-related toxicity. *Future Oncol.* 2013 Nov;9(11):1599-607. doi: 10.2217/fon.13.150.PMID: 24156321
183. Catania C, Radice D, Spitaleri G, Adamoli L, Noberasco C, Delmonte A, Vecchio F, **de Braud F**, Toffalorio F, Goldhirsch A, De Pas T. The choice of whether to participate in a phase I clinical trial: increasing the awareness of patients with cancer. An exploratory study. *Psychooncology.* 2013 Oct 10. doi: 10.1002/pon.3424. [
184. Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, **de Braud F**. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. *Am J Clin Oncol.* 2013 Sep 21.[Epub ahead of print]PMID:24064757
185. Pietrantonio F, Perrone F, Biondani P, Maggi C, Lampis A, Bertan C, Venturini F, Tondulli L, Ferrari D, Ricci V, Villa F, Barone G, Bianco N, Ghidini A, Bossi I, Fanetti G, Di Bartolomeo M, **de Braud F**. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy. *Cancer Biol Ther.* 2013 Sep 4;14(12).
186. Pérez-Vargas JC, Biondani P, Maggi C, Gariboldi M, Gloghini A, Inno A, Volpi CC, Gualeni AV, di Bartolomeo M, **de Braud F**, Castano A, Bossi I, Pietrantonio F. Role of cMET in the Development and Progression of Colorectal Cancer. *Int J Mol Sci.* 2013 Sep 3;14(9):18056-77. doi: 10.3390/ijms140918056.
187. Grassi P, Verzoni E, Mariani L, **De Braud F**, Coppa J, Mazzaferro V, Procopio G. Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. *Clin Genitourin Cancer.* 2013 Jun 19. doi:pii: S1558-7673(13)00083-9. 10.1016/j.clgc.2013.04.022.
188. Damian S, Celio L, De Benedictis E, Mariani P, Agustoni F, Ricchini F, **De Braud F**. Is a Dexamethasone-Sparing Strategy Capable of Preventing Acute and Delayed Emesis Caused by Combined Doxorubicin and Paclitaxel for Breast Cancer? Analysis of a Phase II Trial. *Oncology.* 2013 May 22;84(6):371-377.
189. Pietrantonio F, Biondani P, Ciurlia E, Fanetti G, Tessari A, Bertarelli G, Bossi I, Musella V, Melotti F, Di Bartolomeo M, Valvo F, Pellegrinelli A, Milione M, Perrone F, **de Braud F**. Role of BAX for outcome prediction in gastrointestinal malignancies. *Med Oncol.* 2013 Sep;30(3):610. doi: 10.1007/s12032-013-0610-z.
190. Damato A, Pusceddu S, Milione M, Mazzaferro V, Magli M, Seregini E, **De Braud F**, Buzzoni R. Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities. *Tumori.* 2013 Jul-Aug; 99(4):e148-51. doi: 10.1700/1361.15113.

191. Celio L, Ricchini F, **De Braud F**. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. *Patient Prefer Adherence*. 2013 May 7;7:391-400. doi: 10.2147/PPA.S31288.
192. Buzzoni R, Pusceddu S, Damato A, Meroni E, Cumali A, Milione M, Mazzaferro V, **De Braud F**, Spreafico C, Maccauro M, Zaffaroni N, Castellani MR. Malignant pheochromocytoma and paraganglioma: future considerations for therapy. *Q J Nucl Med Mol Imaging*. 2013 Apr 18.
193. Pietrantonio F, **De Braud F**, Da Prat V, Perrone F, Pierotti MA, Gariboldi M, Fanetti G, Biondani P, Pellegrinelli A, Bossi I, Di Bartolomeo M. A review on biomarkers for prediction of treatment outcome in gastric cancer. *Anticancer Res*. 2013 Apr;33(4):1257-66
194. Pusceddu S, Buzzoni R, **De Braud F**. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm? *Ann Oncol*. 2013 May;24(5):1415-6. doi: 10.1093/annonc/mdt102.
195. Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, Graziano P, Pastorino U, Garassino M, **de Braud F**, Papotti M.  $\Delta$ Np63 (p40) Distribution Inside Lung Cancer: A Driver Biomarker Approach to Tumor Characterization. *Int J Surg Pathol*. 2013 Jun;21(3):229-39. doi: 10.1177/1066896913476750.
196. Garassino MC, Platania M, Broggin M, Torri V, **De Braud F**. To Target or Not to Target, That Is the Question. *J Clin Oncol*. 2013 Mar 20;31(9):1254. doi: 10.1200/JCO.2012.45.9818
197. Bampo C, Alessi A, Fantini S, Bertarelli G, **de Braud F**, Bombardieri E, Valvo F, Crippa F, Di Bartolomeo M, Mariani L, Milione M, Biondani P, Avuzzi B, Chiruzzi C, Pietrantonio F. Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?. *Oncology*. 2013 Jan 15;84(4):191-199.
198. Pietrantonio F, Biondani P, Milione M, Melotti F, Bertarelli G, Perrone F, **de Braud F**, Mariani L, Fanetti G, Cortinovis D, Di Bartolomeo M. Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. *Clin Transl Oncol*. 2012 Nov 21. [Epub ahead of print]
199. Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, **de Braud F**. Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. *J Cancer Res Clin Oncol*. 2012 Nov 17.
200. Procopio G, Verzoni E, **de Braud F**. Targeted Therapies and Survival: What We Can Learn from Studies in Advanced Renal Cell Carcinoma. *Oncology*. 2013;84(1):39-42. Epub 2012 Oct 17.
201. Díaz-Rubio E, Pietrantonio F, **de Braud F**. Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. *Oncologist*. 2012;17(11):1426-8. doi: 10.1634/theoncologist.2012-0075.

202. Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, **De Braud F**, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. *Eur J Cancer*. 2012 Oct 8. doi:pii: S0959-8049(12)00723-X. 10.1016/j.ejca.2012.09.009
203. Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, **De Braud F**. Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. *r J Cancer*. 2012 Sep 11. doi: 10.1038/bjc.2012.327.
204. Pietrantonio F, Garassino MC, Torri V, **de Braud F**. Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. *Ann Oncol*. 2012 Aug 8
205. Celio L, Agustoni F, Testa I, Dotti K, **De Braud F**. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. *Tumori*. 2012 May;98(3):279-86.
206. Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, **De Braud F**, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. *Lancet Oncol*. 2012 Aug;13(8):810-6.
207. Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, **De Braud F**, Tomassetti P, Delle Fave G, Falconi M. Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. *Neuroendocrinology* 2012;96:32-40.
208. Perrone F, **de Braud F**, Labianca R, Tomino C, Roila F. Tackling off-label use of anticancer drugs. *Clin Oncol*. 2012 Aug 1;30(22):2800.
209. Pietrantonio F, Biondani P, **de Braud F**, Pellegrinelli A, Bianchini G, Perrone F, Formisano B, Di Bartolomeo M. Bax expression is predictive of favorable clinical outcome in chemo-naïve advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen. *Transl Oncol*. 2012 Jun;5(3):155-9.
210. Pelosi G, Gasparini P, Cavazza A, Rossi G, Graziano P, Barbareschi M, Perrone F, Barberis M, Takagi M, Kunimura T, Yamada T, Nakatani Y, Pastorino U, Scagnatta P, Sozzi G, Garassino M, **De Braud F**, Papotti M. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. *Lung Cancer*. 2012 Sep;77(3):507-14.
211. Biondani P, Procopio G, Pietrantonio F, **de Braud F**, Verzoni E. New perspectives in advanced genitourinary malignancies. *Tumori*. 2012 Mar-Apr; 98(2):267-9.
212. Toffalorio F, Radice D, Spaggiari L, Sinno V, Barberis M, Spitaleri G, Giovannini M, Delmonte A, Catania C, Noberasco C, Brambilla D, **de Braud F**, Veronesi G, Solli P, De Pas T. Features and prognostic factors of large node-negative non-small-cell lung cancers shifted to stage II. *J Thorac Oncol*. 2012 Jul;7(7):1124-30.
213. M. Milione, S. Pusceddu, P. Gasparini, F. Melotti, P. Maisonneuve, V. Mazzaferro, **FG. de Braud** and G. Pelosi Succinate Dehydrogenase B Subunit Immunohistochemical Expression Predicts Aggressiveness in Well Differentiated Neuroendocrine Tumors of

214. Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J; BIG 1-98 Collaborative Group; International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. *Br J Cancer*. 2012 May 8;106(10):1618-25.
215. Procopio G, Verzoni E, **De Braud F**. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. *Eur Urol* 2012; 61:826-33.
216. De Pas T, Giovannini M, Rescigno M, Catania C, Toffalorio F, Spitaleri G, Delmonte A, Barberis M, Spaggiari L, Solli P, Veronesi G, **De Braud F**. Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. *Crit Rev Oncol Hematol*. 2012 Sep;83(3):432-43.
217. Spada F, Pelosi G, Squadroni M, Lorizzo K, Farris A, **de Braud F**, Fazio N. Neuroendocrine tumour arising inside a retro-rectal tailgut cyst: report of two cases and a review of the literature. *Ecancermedalscience*. 2011;5:201.
218. Eigentler TK, Weide B, **de Braud F**, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C. A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma. *Clin Cancer Res*. 2011 Dec 15;17(24):7732-42. Epub 2011 Oct 25. PubMed PMID: 22028492.
219. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B, **de Braud F**; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol*. 2011 Nov;12(12):1101-8. Epub 2011 Oct 20. PubMed PMID: 22018631; PubMed Central PMCID: PMC3235950.
220. Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlertsen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS, **de Braud F**; BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat*. 2012 Jan;131(1):295-306. Epub 2011 Sep 4. PubMed PMID: 21892704.
221. De Pas T, Toffalorio F, Manzotti M, Fumagalli C, Spitaleri G, Catania C, Delmonte A, Giovannini M, Spaggiari L, **de Braud F**, Barberis M. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. *J Thorac Oncol*. 2011 Nov;6(11):1895-901.
222. Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD, **de Braud F**; International Breast Cancer Study Group and BIG 1-98 Collaborative Group. Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal

women with hormone receptor-positive, early breast cancer. *Breast Cancer Res.* 2011 May 26;13(3):209.

223. De Pas T, Rosati G, Spitaleri G, Boni C, Tucci A, Frustaci S, Scalamogna R, Radice D, Boselli S, Toffalorio F, Catania C, Noberasco C, Delmonte A, Vecchio F, **de Braud F**. Optimizing clinical care in patients with advanced soft tissue sarcoma: a phase II study of a new schedule of high-dose continuous infusion ifosfamide and doxorubicin combination. *Chemotherapy.* 2011;57(3):217-24.
224. Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, **De Braud F**, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. *J Clin Oncol.* 2011 Jun 10;29(17):2372-7.
225. Joensuu H, **De Braud F**, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. *Br J Cancer.* 2011 May 24;104(11):1686-90.
226. Haller DG, Tabernero J, Maroun J, **de Braud F**, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. *J Clin Oncol.* 2011 Apr 10;29(11):1465-71.
227. De Pas TM, Toffalorio F, Giovannetti E, Radice D, Russo F, Angeli I, Calamai G, Spitaleri G, Catania C, Noberasco C, Milani A, Pelosi G, Danesi R, **De Braud F**. Optimizing pemetrexed-gemcitabine combination in patients with advanced non-smallcell lung cancer: a pharmacogenetic approach. *J Thorac Oncol.* 2011 Apr;6(4):768-73.
228. Gregorc V, **De Braud FG**, De Pas TM, Scalamogna R, Citterio G, Milani A, Boselli S, Catania C, Donadoni G, Rossoni G, Ghio D, Spitaleri G, Ammannati C, Colombi S, Caligaris-Cappio F, Lambiase A, Bordignon C. Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. *Clin Cancer Res.* 2011 Apr 1;17(7):1964-72.
229. Bokemeyer C, Bondarenko I, Hartmann JT, **de Braud F**, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol.* 2011 Jan 12.
230. Jonker DJ, Rosen LS, Sawyer MB, **de Braud F**, Wilding G, Sweeney CJ, Jayson GC, McArthur GA, Rustin G, Goss G, Kantor J, Velasquez L, Syed S, Mokliatchouk O, Feltquate DM, Kollia G, Nuyten DS, Galbraith S. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. *Ann Oncol.* 2011 Jun;22(6):1413-9.
231. Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, **de Braud F**. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas. *Cancer Treat Rev.* 2010 Nov;36 Suppl 3:S87-94. Review.
232. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, **de Braud F**. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase



I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. *Eur J Cancer*.2010 Nov;46(16):2926-35.

233. Santoro A, Pressiani T, Citterio G, Rossoni G, Donadoni G, Pozzi F, Rimassa L, Personeni N, Bozzarelli S, Rossoni G, Colombi S, **De Braud FG**, Caligaris-Cappio F, Lambiase A, Bordignon C. Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma. *Br J Cancer*. 2010 Sep 7;
234. De Pas T, **de Braud F**, Veronesi G. Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process. *J Thorac Oncol*. 2010 May;5(5):754.
235. Gregorc V, Zucali PA, Santoro A, Ceresoli GL, Citterio G, De Pas TM, Zilembo N, De Vincenzo F, Simonelli M, Rossoni G, Spreafico A, Grazia Viganò M, Fontana F, **De Braud FG**, Bajetta E, Caligaris-Cappio F, Bruzzi P, Lambiase A, Bordignon C. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. *J Clin Oncol*. 2010 May 20;28(15).
236. Roila F, Ballatori E, Labianca R, **De Braud F**, Borgonovo K, Martelli O, Gallo C, Tinazzi A, Perrone F; Italian Medical Oncology Association (AIOM). Off-label prescription of antineoplastic drugs: an Italian prospective, observational, multicenter survey. *Tumori*. 2009 Nov-Dec;95(6):
237. Catania C, De Pas T, Minchella I, **De Braud F**, Micheli D, Adamoli L, Spitaleri G, Noberasco C, Milani A, Zampino MG, Toffalorio F, Radice D, Goldhirsch A, Nolè F. "Waiting and the Waiting Room: How Do You Experience Them?" Emotional Implications and Suggestions from Patients with Cancer. *J Cancer Educ*. 2010 Mar 4.
238. Labianca R, Beretta GD, Kildani B, Milesi L, Merlin F, Mosconi S, Pessi MA, Prochilo T, Quadri A, Gatta G, **de Braud F**, Wils J. Colon cancer. *Crit Rev Oncol Hematol*. 2010 May;74(2):106-33.
239. De Pas T, Raimondi S, Pelosi G, Spaggiari L, **De Braud F**, Veronesi G, Maisonneuve P. A critical appraisal of the adjuvant chemotherapy guidelines for patients with completely resected T3N0 non-small-cell lung cancer. *Acta Oncol*. 2010 May;49(4).
240. Catania C, Pelosi G, Fazio N, Biffi R, Spitaleri G, Noberasco C, Zampino MG, Maggioni A, Trifirò G, Toffalorio F, Vigna PD, **De Braud F**, De Pas T. A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma. *Acta Oncol*. 2010;49(1):120-1.
241. Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, Curigliano G, de Pas T, Jemos C, Omodeo Salè E, Boselli S, **de Braud F**. Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. *Oncology*. 2009;77(6):358-65
242. Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R, **de Braud F**. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. *Pharmacogenomics J*. 2010 Jun;10(3):180-90.
243. De Pas TM, Toffalorio F, Catania C, Noberasco C, Spitaleri G, Spaggiari L, **De Braud F**. Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration. *Ann Oncol*. 2009 Oct;20(10):1747-8. Epub 2009 Aug 18.

244. Fazio N, Luca F, Monfardini L, Pelosi G, Bodei L, Lorizzo K, Di Meglio G, Gibelli B, Ravizza D, Bonomo G, Grana CM, Baio S, Squadroni M, Paganelli G, **de Braud F**. Right pelvic mass in a patient with a radically resected carcinoid of the appendix. *Gut*. 2009 Sep;58(9)
245. Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. *Eur J Cancer*. 2009 Aug;45(12):2116-22
246. Curigliano G, Spitaleri G, De Cobelli O, Scardino E, Sbanotto A, **de Braud F**. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. *Urol Int*. 2009; 82(2):196-202
247. Capurso G, Fazio N, Festa S, Panzuto F, **de Braud F**, Delle Fave G. Molecular target therapy for gastroenteropancreatic endocrine tumours: Biological rationale and clinical perspectives. *Crit Rev Oncol Hematol*. 2009 Feb 25.
248. Zampino MG, Magni E, Leonardi MC, Petazzi E, Santoro L, Luca F, Chiappa A, Petralia G, Trovato C, Fazio N, Orecchia R, Nolè F, **de Braud F**. Capecitabine Initially Concomitant to Radiotherapy Then Perioperatively Administered in Locally Advanced Rectal Cancer. *Int J Radiat Oncol Biol Phys*. 2009 Feb 9.
249. Catalano G, De Pas T, Spaggiari L, Gandini S, Jerezek-Fossa BA, **de Braud F**, Leo F, Veronesi G, Orecchia R. Three-times daily radiotherapy after chemotherapy in stage III non-small cell lung cancer. Single-institution prospective study. *Anticancer Res*. 2008 Nov-Dec; 28(6B):4121-7.
250. Biffi R, Orsi F, Pozzi S, Pace U, Bonomo G, Monfardini L, Della Vigna P, Rotmensz N, Radice D, Zampino MG, Fazio N, **de Braud F**, Andreoni B, Goldhirsch A. Best choice of central venous insertion site for the prevention of catheter-related complications in adult patients who need cancer therapy: a randomized trial. *Ann Oncol*. 2009 Jan 29
251. Spitaleri G, Matei DV, Curigliano G, Detti S, Verweij F, Zambito S, Scardino E, Rocco B, Nolè F, Ariu L, De Pas T, **de Braud F**, De Cobelli O. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. *Ann Oncol*. 2009 Mar; 20(3):498-502. Epub 2009 Jan 12. PubMed PMID: 19139180; PubMed Central PMCID: PMC2648011.
252. Sessa C, Perotti A, Noberasco C, **De Braud F**, Gallerani E, Cresta S, Zucchetti M, Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. *Eur J Cancer*. 2009 May; 45(7):1153-61. Epub 2008 Dec 27. PubMed PMID: 19114300.
253. De Pas T, Spitaleri G, Pelosi G, De Carlis L, Lorizzo K, Locatelli M, Curigliano G, Toffalorio F, Catania C, **de Braud F**. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. *J Thorac Oncol*. 2009 Jan; 4 (1):138-9..
254. Zampino MG, Labianca R, Beretta GD, Magni E, Gatta G, Leonardi MC, Chiappa A, Biffi R, **de Braud F**, Wils J. Rectal cancer. *Crit Rev Oncol Hematol*. 2009 May; 70(2):160-82. Epub 2008 Dec 6.

255. Lorizzo K, Fazio N, Radice D, Boselli S, Ariu L, Zampino MG, Nolè F, Magni E, Ardito R, Minchella I, Rocca A, Di Meglio G, Squadroni M, **de Braud F**. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. *Cancer Chemother Pharmacol*. 2008 Nov 26. [
256. Catania C, De Pas T, Goldhirsch A, Radice D, Adamoli L, Medici M, Verri E, Marengi C, **de Braud F**, Nolè F. Participation in clinical trials as viewed by the patient: understanding cultural and emotional aspects which influence choice. *Oncology*. 2008; 74 (3-4):177-87.
257. De Pas T, Toffalorio F, Colombo P, Trifirò G, Pelosi G, Vigna PD, Manzotti M, Agostini M, **de Braud F**. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. *J Thorac Oncol*. 2008 Aug; 3 (8):938-41.
258. Floriani I, Rotmensz N, Albertazzi E, Torri V, De Rosa M, Tomino C, **de Braud F**. Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: A survey from the Italian National Monitoring Centre for Clinical Trials. *Trials*. 2008 Jul 25; 9:46.
259. Zampino MG, Magni E, Santoro L, Zorzino L, Dell'orto P, Sonzogni A, Fazio N, Monfardini L, Chiappa A, Biffi R, **de Braud F**. Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR positive advanced colorectal cancer treated with gefitinib? *Cancer Chemother Pharmacol*. 2008 Dec; 63 (1):139-48.
260. Curigliano G, Spitaleri G, Fingert HJ, **de Braud F**, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. *Eur J Cancer*. 2008 Mar; 44 (4):494-500.
261. Joensuu H, **De Braud F**, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, Casali PG. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. *Ann Oncol*. 2008 Jan; 19 (1):173-7.
262. De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, Andreoni B, Testori A, **de Braud F**. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. *Crit Rev Oncol Hematol*. 2008 Jan; 65 (1):1-7.
263. Fazio N, Di Meglio G, Lorizzo K, **de Brand F**. Miliary Hepatic Metastases from Neuroendocrine Carcinoma. *Dig Surg*. 2008 Oct 1; 25 (5):330. [Epub ahead of print] No abstract available.
264. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo K, Santoro L, Boselli S, **de Braud F**. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. *Cancer*. 2007 Aug 15; 110 (4):752-8.
265. Zatelli MC, Torta M, Leon A, Ambrosio MR, Gion M, Tomassetti P, **De Braud F**, Delle Fave G, Dogliotti L, Uberti EC; On behalf of the Italian CromaNet Working Group. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. *Endocr Relat Cancer*. 2007 Jun; 14 (2):473-82.
266. De Pas T, Spitaleri G, Pruneri G, Curigliano G, Noberasco C, Luini A, Andreoni B, Testori A, **de Braud F**. Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. *Crit Rev Oncol Hematol*. 2007 Jul 18;

267. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynn-Jones R, Widmer L, Seymour M, **de Braud F**; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. *J Clin Oncol*. 2007 Aug 1;25 (22):3217-23.
268. Curigliano G, **De Braud F**, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nole F, Verweij F, Matei V, De Cobelli O. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. *Anticancer Drugs*. 2007 Sep;18 (8):949-54.
269. Joensuu H, **De Braud F**, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, Casali P. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. *Ann Oncol*. 2007 Aug 14;
270. Fazio N, Biffi R, Curigliano G, Lorizzo K, Zampino MG, **de Braud F**, Chiappa A, Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epirubicin in a randomized controlled trial. *J Natl Cancer Inst*. 2007 Sep 5;99 (17):1345-6; author reply 1346-7.
271. Milani A, De Pas T, Noberasco C, McDonnell C, Libutti L, Limardi I, Zencovich C, Boselli S, Bianchi M, **de Braud F**. A 15-min premedication for 1-h paclitaxel infusion: optimizing patients' care. *Lung Cancer*. 2007 Nov;58 (2):300-1.
272. Curigliano G, Spitaleri G, Fingert HJ, **de Braud F**, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. *Eur J Cancer*. 2007 Nov 15;
273. Zampino MG, Magni E, Massacesi C, Zaniboni A, Martignetti A, Zorzino L, Lorizzo K, Santoro L, Boselli S, **de Braud F**. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. *Cancer*. 2007 Aug 15;110 (4):752-8.
274. Veronesi G, Scanagatta P, Leo F, De Pas T, Pelosi G, Catalano G, Gandini S, **deBraud F**, Spaggiari L. Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer. *J Thorac Oncol*. 2007 Feb; 2 (2):131-4.
275. Curigliano G, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, Spitaleri G, **de Braud F**. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. *Prostate*. 2007 Feb 8;
276. Schmoll HJ, Cartwright T, Tabernero J, Nowacki MP, Figer A, Maroun J, Price T, Lim R, Van Cutsem E, Park YS, McKendrick J, Topham C, Soler-Gonzalez G, **de Braud F**, Hill M, Sirzen F, Haller DG. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. *J Clin Oncol*. 2007 Jan 1;25 (1):102-9.
277. De Pas TM, **de Braud F**, Catalano G, Putzu C, Veronesi G, Leo F, Solli PG, Brambilla D, Paganelli G, Spaggiari L. Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. *Ann Thorac Surg*. 2007 Jan;83 (1):231-4.

278. Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, **De Braud F**, Loli P, Tartaglia A, Bajetta R, Ferrari L. Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study. *Cancer*. 2006 Nov 15;107 (10):2474-81.
279. De Pas T, Putzu C, Curigliano G, Noberasco C, Sabrina B, Catania C, Orlando L, Milani A, Spaggiari L, **de Braud F**. A proper schedule of weekly paclitaxel and gemcitabine combination is highly Active and very well tolerated in NSCLC patients. *Lung Cancer*. 2006 Dec;54 (3):359-64.
280. Curigliano G, Spitaleri G, **de Braud F**, Goldhirsch A. Reply to Letter to the Editor: 'Toxic epidermal necrolysis in patients with malignancies', by G. Gravante, G. Esposito, M. Marianetti, D. Delogu, G. Sconocchia & A. Montone (doi:10.1093/annonc/mdl089). *Ann Oncol*. 2006 Oct;17 (10):1601-2.
281. Mey V, Giovanetti E, **de Braud F**, Nannizzi S, Curigliano G, Verweij F, de Corbelli O, Pece S, Tacca MD, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. *Br J Cancer*. 2006 Jul 25
282. Fazio N, Grana C, Pelosi G, Torrisi R, Di Meglio G, Tradati N, Lorizzo K, **de Braud F**. Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal aggressive neuroendocrine carcinoma. *Acta Oncol*. 2006;45 (5):627-9
283. Zampino MG, Lorizzo K, Rocca A, Locatelli M, Zorzino L, Manzoni S, Mazzetta C, Fazio N, Biffi R, **de Braud F**. Oxaliplatin combined with 5-fluorouracil and methotrexate in advanced colorectal cancer. *Anticancer Res*. 2006 May-Jun; 26 (3B).2425-8
284. Fazio N, **de Braud F**, Fave GD, Oberg K. Interferon- $\alpha$  and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma : single agent or combination ? *Ann Oncol*.2006 Jun 23
285. Humbert M, Doumerc N, **de Braud F**, Fofana M, Blanchet P. Self-retaining ureteric removal of an encrusted ureteric stent after 10 years *Prog Urol*. 2006 Apr;16 (2):204-7.
286. Curigliano G, Magni E, Renne G, de Corbelli O, Rescigno M, Torrisi R, Spitaleri G, Pietri E, **de Braud F**, Goldhirsch A. "Burned out" phenomenon of the testis in retroperitoneal seminoma. *Acta Oncol*. 2006;45 (3):335-6
287. Curigliano G, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, **de Braud F**, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol*. 2006 Jul; 17(7):1174-5.
288. Bracarda S, de Corbelli O, Greco C, Prayer-Galetti T, Valdagni R, Gatta G, **de Braud F**, Bartsch G. Cancer of the prostate. *Crit Rev Oncol Hematol*. 2005 Dec; 56 (3):379-96
289. Curigliano G, Spitaleri G, Pietri E, Rescigno M, **de Braud F**, Cardillo A, Munzone E, Rocca A, Bonizzi G, Bricard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? *Ann Oncol*. 2006 May; 17(5):750-62.
290. Leon A, Torta M, Dittadi R, degli Uberti E, Ambrosio MR, Delle Fave G, **de Braud F**, Tomassetti P, Gion M, Dogliotti L. Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study. *Int J Biol Markers*. 2005 Jul-Sep; 20(3):156-

291. Curigliano G, Colleoni M, Mandala M, De Pas T, Spitaleri G, **de Braud F**, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. *J Clin Oncol*. 2005 Oct 1; 23(28):7243-4; author reply 7244.
292. Curigliano G, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, **de Braud F**, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic Effects of Surgery : Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-beta) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. *Breast Cancer Res Treat*. 2005 Sep.; 93(1):35-40
293. De Pas T, Putzu C, Pelosi G, Curigliano G, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, **de Braud F** Target-treatment and patients' selection: can we still neglect the timing of tissue collection? *J Clin Oncol*. 2005 Sep 1; 23(25):6275-5;author reply 6275-6.
294. Twelves CJ, Butts CA, Cassidy J, Conroy T, de Braud F, Diaz-Rubio E, Taberero JM, Schoffski P, Figuer A, Brunet R, Grossmann J, Sobrero AF, Van Cutsem EJ. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. *Cli Colorectal Cancer*. 2005 Jul; 5 (2):101-7.
295. Catalano G, Jereczek-Fossa BA, De Pas T, Leon ME, Cattani F, Spaggiari L, Veronesi G, **de Braud F**, Orecchia R. Three-Times-Daily Radiotherapy with Induction Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer Feasibility and Toxicity Study. *Strahlenther Onkol*. 2005 Jun; 181(6):363-371.
296. Catalano V, Labianca R, Beretta GD, Gatta G, **de Braud F**, Van Cutsem E. Gastric Cancer. *Crit Rev Oncol Hematol*. 2005 Jun;54 (3):209-41
297. Veronesi G, Pelosi G, Sonzogni A, Leon ME, D'Aiuto M, Gasparri R, **de Braud F**, De Pas T, Sandri M, Spaggiari L. Tumor CEA as predictor of better outcome in squamous cell carcinoma of the lung. *Lung Cancer*. 2005 May; 48(2):233-40.
298. Allavena P, Signorelli M, Chieppa M, Erba E, Bianchi G, Marchesi F, Olimpio CO, Bonardi C, Garbi A, Dissoni A, **de Braud F**, Jimeno J, D'Incalci M. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. *Cancer Res*. 2005 Apr 1; 65(7):2964-71.
299. Mallik S, de Braud F, Fofana M, Humbert M, Clervil M, Blanchet P. Wich anaesthesia should be recommended for prostate biopsy? *West Indian Med J*. 2005 Mar; 54(2):135-8
300. Sessa C, **de Braud F**, Perotti A, Bauer J, Curigliano G, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'Po E, Colombo N. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. *J Cli Oncol*. 2005 Mar 20; 23 (9):1867-74.
301. **de Braud F**, De Pas T, Spaggiari L, Veronesi G, Curigliano G, Noberasco C, Pelosi G, Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst*. 2005 Mar 16; 97(6):461-2; author reply 462-3.
302. De Pas T, Sbanotto A, Catania C, Banfi MG, Curigliano G, Nole F, Fazio N, Formica V, Veronesi G, **de Braud F**. Oral administration of vinorelbine can overcome intractable

- endovenous-vinorelbine-associated acute tumor pain. *Support Care Cancer*. 2005 Mar; 13(3):194-5.
303. De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, Curigliano G, Manzoni S, Goldhirsch A, **de Braud F**. Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V.R. Rozados et al. (*Ann Oncol* 2004;15:1543-1550): and in humans? *Ann Oncol*. 2005 Apr; 16(4):673.
304. Noberasco C, De Pas T, Curigliano G, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, **de Braud F**. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer? *J Clin Oncol*. 2005 Feb 1; 23(4):921-2; author reply 922.
305. Spaggiari L, D'Aiuto M, Veronesi G, Pelosi G, de Pas T, Catalano G, **de Braud F**. Extended pneumonectomy with partial resection of the left atrium, without cardiopulmonary bypass, for lung cancer. *Ann Thorac Surg*. 2005 Jan; 79 (1):234-40.
306. De Pas T, Pelosi G, **de Braud F**, Veronesi G, Curigliano G, Leon ME, Danesi R, Noberasco C, D'Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. *J Clin Oncol*. 2004 Dec 15; 22 (24):4966-70.
307. Fazio N, De Pas T, **de Braud F**, Spaggiari L, Mazzarol G, Biffi R, Andreoni B, Zampino M, Curigliano G, Lorizzo K, Di Meglio G, Goldhirsch A. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. *Ann Oncol*. 2004 Dec; 15 (12):1850.
308. Chiappa A, Zbar AP, Biffi R, Bellomi M, Orecchia R, Marsiglia H, Bertani E, **de Braud F**, Crotti C, Andreoni B. Primary and recurrent retroperitoneal sarcoma: factors affecting survival and long-term outcome. *Hepatogastroenterology*. 2004 Sep-Oct; 51 (59):1304-9.
309. De Pas T, Curigliano G, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, **de Braud F**. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2-stage IIIb non-small-cell lung cancer: a prospective phase-II study. *Bull Cancer*. 2004 Sep 1; 91 (9):E273-7. Print 2004 Sep.
310. Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrada S, Nole F, **de Braud F**, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. *Cancer*. 2004 Sep 15; 101 (6):1302-10.
311. Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, **de Braud F**. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. *Eur J Cancer*. 2004 Aug; 40 (12):1872-7
312. Labianca R, Beretta G, Gatta G, **de Braud F**, Wils J. Colon cancer *Crit Rev Oncol Hematol*. 2004 Aug; 51 (2):145-70.
313. Jereczek-Fossa BA, Morra A, **de Braud F**, Alterio D, Mazzetta C, Rocca A, Catalano G, Bianchi L, Pasetti M, Chiesa F, Bruschini R, Orecchia R. Hyperfractionated Radiotherapy in Locally Advanced Nasopharyngeal Cancer: An Analysis of 43 Consecutive

Patients. *Strahlenther Onkol.* 2004 Jul; 180 (7):425-33.

314. Cassidy J, Taberero J, Twelves C, Brunet R, Butts C, Conroy T, **de Braud F**, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A, Van Cutsem E, Diaz-Rubio E. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. *J Clin Oncol.* 2004 Jun 1; 22 (11):2084-91.
315. Curigliano G, Cipolla C, **de Braud F**. Drug-induced prolongation of the QT interval. *N Engl J Med.* 2004 Jun 17; 350 (25):2618-21
316. **de Braud F**, Cascinu S, Gatta G. Cancer of pancreas. *Crit Rev Oncol Hematol.* 2004 May; 50 (2):147-55
317. Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, **de Braud F**. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. *Ann Oncol.* 2004 May; 15 (5):759-64.
318. Leo F, Solli P, Spaggiari L, Veronesi G, **de Braud F**, Leon ME, Pastorino U. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? *Ann Thorac Surg.* 2004 Jan; 77 (1):260-5; discussion 265.
319. Loni L, **de Braud F**, Zinzani PL, Danesi R. Pharmacogenetics and proteomics of anticancer drugs in non-Hodgkin's lymphoma. *Leuk Lymphoma.* 2003;44 Suppl 3: S115-22.
320. Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, Curigliano G, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, **de Braud F**. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. *Anticancer Res.* 2003 Nov-Dec; 23 (6D):5023-30
321. Stahel R, Rossi A, Petruzella L, Kosimidis P, **de Braud F**, Bernardo MM, Souquet PJ, Parra HS, Gridelli C. Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations. *Br J Cancer.* 2003 Dec; 89 Suppl 2:S19-23
322. De Pas T, Danesi R, Catania C, Curigliano G, **de Braud F**; Italia Sarcoma Group. Imatinib administration in two patients with liver metastases from GIST and severe jaundice *Br J Cancer.* 2003 Oct 20; 89 (8):1403-4
323. Danesi R, **de Braud F**, Fogli S, De Pas T, Di Paolo A, Curigliano G, Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. *Pharmacol Rev* 2003 Mar; 55(1): 57-103.
324. De Pas T, Bodei L, Pelosi G, **de Braud F**, Villa G, Capanna R, Paganelli G. Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group. *British Journal of Cancer* 2003 Mar 10; 88 (5):645-7
325. **de Braud F**, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma *Crit Rev Oncol Hematol.* 2003 Jul; 47 (1):35-63. Review
326. Veronesi G, Spaggiari L, De Pas T, Solli PG, **de Braud F**, Catalano GP, Curigliano G, Leo F, Pastorino U. Preoperative chemotherapy is essential for conservative surgery of Askin tumors. *Journal of Thoracic and Cardiovascular Surgery* 2003 Feb; 125 (2): 428-9
327. Ravizza D, Fazio N, Fiori G, Crosta C, Orsi F, Grasso R, Medici M, Ferretti G, **de Braud F**. Iatrogenic gastroduodenal ulcers during hepatic intra-arterial chemotherapy.



328. De Pas T, Casali PG, Toma S, Romanini A, Massidda B, Comandone A, Labianca R, Massacesi C, Tucci A, Antimi M, Biasco G, Agliettaq M, Apice G, **de Braud F**. Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas? *Oncology* 2003; 64 (2): 186-8
329. Orecchia R, Jereczek-Fossa BA, Catalano G, Chiesa F, De Pas T, Masci G, Krenqli M, Vavassori A, De Paoli F, Robertson C, Marrocco E, **de Braud F**. Phase II trial of vinorelbine, cisplatin and continuous infusion of 5-fluorouracil followed by hyperfractionated radiotherapy in locally advanced head and neck cancer. *Oncology* 2002; 63 (2): 115-23
330. Curigliano G, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, **de Braud F**, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. *Annals of Oncology* 2002 Jun; 13 (6): 895-902
331. De Pas T, Pastorino U, Spaggiari L, Curigliano G, **de Braud F**, Robertson C. Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. *Journal of Clinical Oncology* 2002 May 15; 20 (10): 2603-4
332. Veronesi G, Solli PG, Leo F, D'Aiuto M, Leon ME, **de Braud F**, Spaggiari L, Pastorino U. Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer. *Lung Cancer* 2002 Apr; 36 (1): 91-7
333. Curigliano G, Ferretti G, Mandala M, De Pas T, Calabro MG, Solli P, Noberasc C, **de Braud F**. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. *Anticancer Research* 2001 Sep-Oct; 21 (5): 3461-9
334. **de Braud F**, Maffezzini M, Vitale V, Bruzzi P, Gatta G, Hendry WF, Sternberg CN. Bladder cancer. *Critical Review of Oncology and Hematology* 2002 Jan; 41 (1): 89-106
335. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, **de Braud F**. Gemcitabine-induced systemic capillary leak syndrome. *Annals of Oncology* 2001 Nov; 12 (11): 1651-2
336. Fogli S, Danesi R, **de Braud F**, De Pas T, Curigliano G, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. *Annals of Oncology* 2001 Nov; 12 (11): 1553-9
337. Pfister CU, Martoni A, Zamagni C, Lelli G, **de Braud F**, Souppart C, Duval M, Hornberger U. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. *Biopharmaceutics and Drug Disposition* 2001 Jul; 22 (5): 191-7
338. Curigliano G, Ferretti G, Flamini G, Goldhirsch A, **de Braud F**, Calabro MG, Mandala M, Nole F, De Pas T, D'Addressi A, Cittadini A. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. *Anticancer Research* 2001; 21: 3015-20
339. Biffi R, Pozzi S, Pace U, Cenciarelli S, Zambelli M, Orsi F, Grasso RF, **de Braud F**, Andreoni B. Is there a real advantage in utilizing central venous ports in oncology surgery?

340. Biffi R, **de Braud F**, Orsi F, Pozzi S, Arnaldi P, Goldhirsch A, Rotmensz N, Robertson C, Bellomi M, Andreoni B. A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients. *Cancer* 2001; 92: 1204-12
341. Danesi R, **de Braud F**, Fogli S, Di Paolo A, Del Tacca M. Pharmacogenetic determinants of anti-cancer drug activity and toxicity. *Trends in Pharmacological Sciences* 2001; 22: 420-6
342. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, **de Braud F**. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide. *European Journal of Nuclear Medicine* 2001; 28: 426-34
343. De Pas T, Catalano G, Pastorino U, **de Braud F**, Jerezek-Fossa B, Spaggiari L, Orecchia R. Very low acute toxicity of three fractions per day accelerated radiotherapy given after Induction chemotherapy and surgery in stage III non-small cell lung cancer. *Lung Cancer* 2000; 30: 149-50
344. Martinoni A, Cipolla CM, Civelli M, Cardinale D, Lamantia G, Colleoni M, DeBraud F, Susini G, Martinelli G, Goldhirsh A, Fiorentini C. Intrapericardial treatment of neoplastic pericardial effusions. *Herz*. 2000 Dec;25 (8):787-93. Review.
345. De Pas T, **de Braud F**, Mandala M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P, Goldhirsch A. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. *Lung Cancer* 2001; 31: 267-70
346. Biffi R, Orsi F, Grasso F, **De Braud F**, Cenciarelli S, Andreoni B. Catheter rupture and distal embolisation: a rare complication of central venous ports. *J Vasc Access*. 2000 Jan-Mar;1 (1):19-22.
347. Orsi F, Grasso RF, Arnaldi P, Bonifacio C, Biffi R, **De Braud F**, Bellomi M. Ultrasound guided versus direct vein puncture in central venous port placement. *J Vasc Access*. 2000 Apr-Jun; 1 (2):73-7.
348. De Pas T, **de Braud F**, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, Del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. *Annals of Oncology* 2000; 11: 821-7
349. Giavazzi R, Albini A, Bussolino F, **de Braud F**, Presta M, Ziche M, Costa A. The biological basis for antiangiogenic therapy *Eur J Cancer*. 2000 Oct; 36 (15): 1913-8
350. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, **de Braud F**, Wilson C, Morvan F, Bonetti A. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *Journal of Clinical Oncology* 2000; 18: 2938-47
351. Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabro MG, De Pas T, Orlando L, Mandala M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, **de Braud F**, Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable

non-small cell lung cancer. *Clinical Cancer Research* 2000; 6: 2393-400

352. De Pas T, Curigliano G, Catania C, Comandone A, **de Braud F**. Ifosfamide in the elderly: clinical considerations for a better drug management. *Critical Reviews in Oncology and Hematology* 2000; 33: 129-35
353. Orlando L, Colleoni M, Nole F, Biffi R, Rocca A, Curigliano G, Ferretti G, Peruzzotti G, **de Braud F**, Masci G, Goldhirsch A. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? *Annals of Oncology* 2000; 11: 117-8
354. Biffi R, Pozzi S, Orsi F, **de Braud F**, Cenciarelli S, Andreoni B. Catheter rupture and distal embolisation: a rare complication of central venous ports. *Journal of Vascular Access* 2000; 1: 19-22
355. De Pas T, Martinelli G, **de Braud F**, Peccatori F, Catania C, Aapro M, Goldhirsch A. Friedreich's ataxia and intrathecal chemotherapy in a patient with lymphoblastic lymphoma. *Annals of Oncology* 1999; 10: 1393
356. Brienza S, Bensmaine MA, Soulie P, Louvet C, Gamelin E, Francois E, Ducreux M, Marty M, Andre T, **de Braud F**, Bleiberg H, Segal V, Itzhaki M, Cvitkovic E. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. *Annals of Oncology* 1999; 10: 1311-6
357. Nole F, Minchella I, Colleoni M, Orvieto E, Munzone E, **de Braud F**, Peruzzotti G, Martinelli G, Zampino MG, Catania C, Pizzamiglio M, Veronesi P, Zurrada S, Galimberti V, Goldhirsch A, Veronesi U. Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN). *Annals of Oncology* 1999; 10: 993-6
358. Casali P, Licitra L, Tondini C, **de Braud F**, Bruzzi P, Costa A, Cavalli F. START: a European state-of-the-art on-line instrument for clinical oncologists. *Annals of Oncology* 1999; 10: 769-73
359. Zampino MG, Colleoni M, Bajetta E, Stampino CG, Guenzi A and **de Braud F**. Pharmacokinetics of oral doxifluridine in patients with colorectal cancer. *Tumori* 1999; 85: 47-50
360. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, **de Braud F**, Robertson C, Zurrada S, Casadio C, Zoboli S, Siccardi AG, Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. *European Journal of Nuclear Medicine* 1999; 26: 348-57
361. Crosta C, Fiori G, **de Braud F**. Endoscopic therapy of metastatic melanoma to the papilla of water: a case report. *Giornale Italiano di Endoscopia Digestiva* 1999; 22: 157-9
362. Colleoni M, Vicario G, Manente P, **de Braud F**, Fazio N, Liessi G. Activity and tolerability of courses of intra-arterial chemotherapy followed by chemoembolization in unresectable hepatocellular carcinoma. *Tumori* 1998; 84: 673-6
363. De Pas T, **de Braud F**, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? *Annals of Oncology* 1998; 9: 917-9

364. Jereczek-Fossa B, **de Braud F**, Gasparetto M, De Pas T, Tradati N, Leonardi MC, Marsiglia HR, Orecchia R. Induction chemotherapy followed by simultaneous hyperfractionated radiochemotherapy in advanced head and neck cancer. A pilot study. *Strahlenther Onkologie* 1998; 174: 457-61
365. Biffi R, **de Braud F**, Orsi F, Pozzi S, Mauri S, Goldhirsch A, Nole F, Andreoni B. Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days. *Annals of Oncology* 1998; 9: 767-73
366. Paganelli G, Orecchia R, Jereczek-Fossa B, Grana C, Cremonesi M, **de Braud F**, Tradati N, Chinol M. Combined treatment of advanced oropharyngeal cancer with external radiotherapy and three-step radioimmunotherapy. *European Journal of Nuclear Medicine* 1998; 25: 1336-9
367. Audisio RA, **de Braud F**, Wils J. Gastric cancer. *Critical Reviews in Oncology and Hematology* 1998; 27: 143-4
368. Diaz-Rubio E, Sastre J, Zaniboni A, Labianca R, Cortes-Funes H, **de Braud F**, Boni C, Benavides M, Dallavalle G, Homerin M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. *Annals of Oncology* 1998; 9: 105-8
369. Audisio RA, **de Braud F**, Wils J. Colorectal cancer. *Critical Reviews in Oncology and Hematology* 1998; 27: 139-41
370. De Pas T, **de Braud F**, Sessa C, Sbanotto A, Catania C, Zampino G, Minchella I, Cinieri S, Colleoni M, Nolè F, Ghilenzan S, Marrocco E and Goldhirsch A. A Phase I dose-escalation study with weekly taxol and gemcitabine in patients with advanced non small cell lung cancer. *Bulletin du Cancer* 1998; 18 : 179-83
371. Fazio N, **de Braud F**, Colleoni M, Orsi F, Marengi C, Oliva C, De Pas T, Locatelli M and Goldhirsch A. Hepatic intra-arterial chemotherapy with fluorouracil, cisplatin and mitomycin-c in liver metastases from colorectal carcinoma by percutaneous catheter. *Bulletin du Cancer* 1998; 18: 120-3
372. Colleoni M, Audisio RA, **de Braud F**, Fazio N, Martinelli G, Goldhirsch A. Practical considerations in the treatment of hepatocellular carcinoma. *Drugs* 1998; 55: 367-82
373. **de Braud F**, Munzone E, Nole F, De Pas T, Biffi R, Brienza S, Aapro MS. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. *American Journal of Clinical Oncology* 1998; 21: 279-83
374. Nole F, **de Braud F**, Aapro M, Minchella I, De Pas M, Zampino MG, Monti S, Andreoni G, Goldhirsch A. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. *Annals of Oncology* 1997; 8: 865-70
375. Biffi R, Corrado F, **de Braud F**, de Lucia F, Scarpa D, Testori A, Orsi F, Bellomi M, Mauri S, Aapro M, Andreoni B. Long-term, totally implantable central venous access ports connected to a Groshong catheter for chemotherapy of solid tumours: experience from 178 cases using a single type of device. *European Journal of Cancer* 1997; 33: 1190-4
376. Colleoni M, Graffeo R, Martinelli G, Ghielmini M, **de Braud F**, Zampino G, Marini

- G, Cavalli F and Goldhirsch A Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors. *Oncology Reports* 1997; 4: 913-6
377. **de Braud F**, Fazio N, Aapro M. Hormone replacement therapy and melanoma. *CME Journal of Gynecology and Oncology* 1997; 15-7
378. Peccatori F, **de Braud F**, Cocorocchio E, Aapro M Estrogen replacement therapy and colorectal cancer: suggestion of protection. *CME Journal of Gynecology and Oncology* 1997; 21-2
379. Janot F, Klijanienko J, Russo A, Mamet JP, **de Braud F**, El-Naggar AK, Pignon JP, Luboinski B, Cvitkovic E. Prognostic value of clinicopathological parameters in head and neck squamous cell carcinoma: a prospective analysis. *British Journal of Cancer* 1996; 73: 531-8
380. **de Braud F**, De Pas T, Maffezzini M Immunoterapia del carcinoma renale avanzato. *Urologia* 1996: 451-7
381. Aapro MS, **de Braud F**, Tommasello G. *Oncologie Médicale. Médecine et Hygiene* 1996; 54, 35-8
382. Munzone E, **de Braud F**, de Pas M, Zimatore M, Aapro MS. Le traitement adjuvant des tumeurs du colon et du rectum. *Médecine et Hygiene* 1996; 54, 1216-22
383. Klijanienko J, el-Naggar AK, **de Braud F**, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Janot F, Luboinski B, Cvitkovic E. Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. *Cancer* 1995; 75: 1649-56
384. Di Bartolomeo M, Bajetta E, **de Braud F**, Bochicchio AM, Gebbia V, Bozzetti F, Doci R, Bonfanti G, Cozzaglio L. Phase II study of the etoposide, leucovorin and fluorouracil combination for patients with advanced gastric cancer unsuitable for aggressive chemotherapy. *Oncology* 1995; 52: 41-4
385. **de Braud F**, Colleoni M, Noli F, Bajetta E. Home treatment with interleukin 2 and beta-interferon in patients with colorectal cancer and hepatocellular carcinoma. *Oncology* 1994; 51: 472-6
386. De Cesare M, Pratesi G, **De Braud F**, Zunino F, Stampino CG. Remarkable antitumor activity of 5'-deoxy-5-fluorouridine in human colorectal tumor xenografts. *Anticancer Research* 1994; 14: 549-54
387. Bajetta E, Di Bartolomeo M, **de Braud F**, Bozzetti F, Bochicchio AM, Comella P, Fagnani D, Farina G, Ferroni C, Franchi R, et al. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. *European Journal of Cancer* 1994; 30A: 596-600
388. **de Braud F** Le rôle de La thérapie medicale dans le traitement des tumeurs de l'estomac. *Médecine et Hygiene* 1994; 52, 2386-9
389. Klijanienko J, el-Naggar A, **De Braud F**, Micheau C, Janot F, Luboinski B, Gentile A, Russo A, Cvitkovic E. Keratins 6, 13 and 19. Differential expression in squamous cell carcinoma of the head and neck. *Anal Quant Cytology and Histology* 1993 Oct; 15 (5): 335-40
390. Gasparini M, Zampino MG, Maffioli L, **de Braud F**, Bombardieri E, Buraggi GL.

Enhancement of in vivo monoclonal antibody targeting with recombinant interferon  $\alpha$  and cytokines. *International Journal of Biological Markers*. 1993; 8: 160-5

391. **de Braud F**, Bajetta E, Zampino MG, Zilembo N and Colleoni M. Systemic treatment of advanced malignant melanoma *International Journal of Oncology* 1993; 2: 245-52
392. **de Braud F**, Biganzoli L, Bajetta E, Colleoni M, Zampino MG. Subcutaneous low-dose interleukin-2 plus alpha interferon in advanced malignant melanoma. *Tumori* 1993; 79: 187-90
393. **de Braud F**, Al-Sarraf M. Diagnosis and management of squamous cell carcinoma of unknown primary tumor site of the neck. *Seminars in Oncology* 1993; 20: 273-8
394. Buzzoni R, Colleoni M, Bajetta E, Nole F, Nelli P, De Palma CA, **de Braud F**. Effective salvage chemotherapy in relapsed or refractory non-Hodgkin's lymphoma. *Annals of Oncology* 1993;4: 251-3
395. Zilembo N, Buzzoni R, Bajetta E, Di Bartolomeo M, **de Braud F**, Castellani R, Maffioli L, Celio L, Villa E, Lorusso V, et al. Salvage treatment after r-interferon alpha-2a in advanced neuroendocrine tumors. *Acta Oncologica* 1993; 32: 245-50
396. Di Bartolomeo M, Bajetta E, Zilembo N, **de Braud F**, Di Leo A, Verusio C, D'Aprile M, Scanni A, Barduagni M, et al, Barduagni A. Treatment of carcinoid syndrome with recombinant interferon alpha-2a. *Acta Oncologica* 1993; 32: 235-8
397. Colleoni M, Bajetta E, **de Braud F**, Zilembo N, Nole F, Nelli P. Reversal of resistance to doxifluridine and fluorouracil in metastatic colorectal cancer: the role of high-dose folinic acid. *Tumori* 1992; 78: 258-61
398. **de Braud F**, Bajetta E, Di Bartolomeo M, Colleoni M. Adjuvant chemotherapy for cancer of gastrointestinal tract: a critical review. *Tumori* 1992; 78: 228-34
399. Colleoni M, Nole F, Di Bartolomeo M, **de Braud F**, Bajetta E. Mitoxantrone in patients affected by hepatocellular carcinoma with unfavorable prognostic factors. *Oncology* 1992; 49: 139-42
400. Capri G, **de Braud F**, Lissoni P, Merson M, Santoro O, Stefanon B, Tana S, Tancini G. Immunodepressione e tumori umani. *NAM* 1991; 7: 4-12
401. Ensley JF, Maciorowski Z, Pietraszkiewicz H, **de Braud F**, Sakr W. Methodology and clinical applications of cellular DNA content parameters determined by flow cytometry in squamous cell cancers of the head and neck. *Cancer Treatment and Research* 1990; 52: 225-42
402. **de Braud F**, Heilbrun LK, Ahmed K, Sakr W, Ensley JF, Kish JA, Tapazoglou E, Al-Sarraf M. Metastatic squamous cell carcinoma of an unknown primary localized to the neck. Advantages of an aggressive treatment. *Cancer* 1989; 64: 510-5
403. **de Braud F** Update on treatment of human neoplasia with interferons in combination with other agents. *Folia Oncologica* 1989; 12-26
404. **de Braud F**, Licitra L. Diagnosi e trattamento dei carcinomi spinocellulare a sede primitiva ignota metastatici ai linfonodi cervicali *Argomenti di Oncologia* 1989; 10: 447-57
405. Orazi A, Sozzi G, Cattoretti G, **de Braud F**, Delia D. Acute leukemia with the (4;11)

chromosome translocation following treatment for Hodgkin's disease: a case study. *Haematologica* 1988; 73: 279-83

406. Campagnari F, Bombardieri E, **de Braud F**, Baldini L, Maiolo AT. Terminal deoxynucleotidyl transferase, TdT, as a marker for leukemia and lymphoma cells. *International Journal of Biological Markers* 1987; 2: 31-42
407. Delia D, Bonati A, Giardini R, Villa S, **de Braud F**, Cattoretti G, Rilke F. Expression of the T1 (CD5, p67) surface antigen in B-CLL and B-NHL and its correlation with other B-cell differentiation markers. *Hematological Oncology* 1986; 4: 237-48
408. Delia D, Cattoretti G, Bonati A, Villa S, **de Braud F**, Buscaglia M. Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization. *Clinical and Experimental Immunology* 1985; 59: 305-14
409. Delia D, Greaves M, Villa S, **de Braud F**. Characterization of the response of human thymocytes and blood lymphocytes to the synergistic mitogenicity of 12-O-tetradecanoylphorbol-13-acetate (TPA)-ionomycin. *European Journal of Immunology* 1984; 14: 720-4
410. Bombardieri E, Campagnari F, **de Braud F**, Clerici L, Maiolo AT, Villa ML, Cappelletti V, Saccani Jotti G, Vezzoni P, Neri A, et al. Analysis of the enzyme terminal deoxyribonucleotidyl transferase in lymphoma and leukemia cells. *Acta Biomedica Ateneo Parmense* 1984; 55: 15-23
411. Campagnari F, Maiolo AT, Bombardieri E, **de Braud F**. Terminal deoxyribonucleotidyl transferase in malignant lymphoma and leukemia. *Giornale di Clinica Medica* 1982; 412